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ABSTRACT 
Cytotoxic lymphocytes, comprising natural killer (NK) cells and CD8+ cytotoxic T cells, 
eradicate infected or malignant cells by release of lytic granules and alarm the immune system 
through production of pro-inflammatory cytokines and chemokines. NK cells and CD8+ T cells 
belong to different arms of the immune system, employing complementary strategies for target 
cell recognition. As part of the innate arm, NK cells sense missing or induced self-molecules by 
an array of germline-encoded activating and inhibitory cell surface receptors. In contrast, 
adaptive CD8+ T cells depend on somatically recombined, clonally distributed T cell receptors 
(TCR) that recognize unique foreign peptides presented by MHC class I on target cells. 
Importantly, while mature NK cells readily kill target cells without prior sensitization, naive CD8+ 
T cells require antigen priming to differentiate into cytotoxic effector and long-lived memory 
cells, providing long-term protection against re-infection. Recently, memory features including 
longevity and recall responses have also been ascribed to differentiated NK cell subsets. The 
work presented in my thesis contributes to our molecular understanding of cytotoxic 
lymphocyte differentiation processes in health and disease. 
Exocytosis of lytic granules containing cytotoxic cargo is tightly controlled, but the 
transcriptional regulation of the factors governing degranulation is poorly understood. In 
paper I, we found that expression of one of those factors, Munc13-4, was induced upon 
cytotoxic lymphocyte maturation and required cooperative binding of the transcription factors 
ELF1 and STAT4 to an evolutionary conserved region in intron 1. Transcription factor-binding 
facilitated chromatin remodeling and DNA accessibility, allowing for enhanced transcription of 
the conventional as well as induction of a newly identified, alternative Munc13-4 isoform that is 
likely to play a central role in lymphocyte cytotoxicity. 
Infection with cytomegalovirus (CMV) in mice and man is associated with expansion and 
persistence of NK cell subsets with enhanced effector function. In paper II, we show that such 
adaptive NK cells display previously unappreciated phenotypic and functional heterogeneity, 
and provide a molecular definition of such diverse subsets. Human adaptive NK cells lacked 
expression of the intracellular signaling molecules FcεRγ, SYK and EAT-2 as well as the 
transcription factor PLZF, thereby altering the signaling properties of key NK cell surface 
receptors and the responsiveness to innate cytokines, respectively. Silencing of signaling 
protein expression correlated with promoter DNA methylation and global DNA methylation 
patterns of adaptive NK cells approximated those of differentiated CD8+ cytotoxic effector 
T cells. Importantly, adaptive NK cells failed to kill activated, autologous T cells, implying a 
functional specialization towards immunosurveillance of infected cells. Moreover, utilizing 
samples from patients with bone marrow disorders associated with GATA2 haploinsufficiency 
(paper III) or acquired PIGA mutations in hematopoietic stem cells (paper IV), we demonstrate 
that adaptive NK cells are long-lived and can persist in settings of hematopoietic stem and 
progenitor cell attrition where canonical NK cells are lost. 
Tissue-resident memory T (TRM) cells provide early, localized adaptive immunity in non-
lymphoid tissues. In paper V, we discovered a functional dichotomy of CD8+ skin TRM cells 
based on expression of the marker CD49a. Upon stimulation, CD49a+ cells produced IFN-γ 
and acquired cytotoxic potential by induction of the lytic granule constituents perforin and 
granzyme B. Primed CD49a+ T cells accumulated in the dermis and epidermis of vitiligo 
lesions, an autoimmune condition characterized by local depigmentation as a result of 
melanocyte destruction. In contrast, CD49a– T cells produced IL-17 and were enriched in 
lesional skin from psoriasis patients, promoting local inflammation.  
These insights shed light on novel mechanisms controlling human cytotoxic lymphocyte 
differentiation and may thus be of potential benefit to health. 
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1 INTRODUCTION 
The world is a dangerous place. The human body is constantly exposed to a myriad of threats 
from both the outside, in the form of infectious agents such as viruses and bacteria, as well as 
the inside in the form of malignant transformation, which may result in cancer. Cells of the 
immune system are specialized to sense changes in the healthy environment and protect 
against infection and malignancy throughout the body. A first line of defense provided by 
rapidly responding cells of the innate immune system recognizes conserved, pathogen 
associated molecular patterns (PAMPs) and danger signals in affected tissues. These innate 
immune cells display broad specificity but have defined roles in the early immune response 
and include granulocytes (neutrophils, basophils, eosinophils and mast cells), innate lymphoid 
cells such as natural killer (NK) cells, as well as macrophages and dendritic cells (DCs). 
Neutrophils engulf and destroy pathogens, while basophils, eosinophils and mast cells release 
inflammatory mediators such as cytokines, enzymes, histamine and reactive oxygen species. 
NK cells directly lyse infected or transformed cells. Macrophages and DCs phagocytose and 
digest pathogens or cellular debris for presentation to T cells of the second line of defense, the 
adaptive immune system. B and T lymphocytes of the adaptive immune system possess 
antigen-specificity mediated by clonally distributed, somatically rearranged antigen receptors. 
They expand massively upon activation and provide long-lasting protection against re-infection 
through formation of persistent memory cells. B cells bind soluble antigen and produce 
antibodies whereas CD4+ and CD8+ T cell subsets recognize peptides presented in the context 
of MHC molecules and orchestrate immune responses through cytokine production or killing of 
infected or neoplastic cells, respectively [1].  
1.1 Cytotoxic Lymphocytes 
Cytotoxic lymphocytes can kill target cells by directed release of cytotoxic granules containing 
perforin, a pore-forming homomultimeric protein, and granzymes, serine proteases initiating 
apoptosis pathways upon delivery to the cytoplasm of target cells [2]. The major cytotoxic 
lymphocyte subsets in humans are natural killer (NK) cells and CD8+ T cells. While NK cells 
belong to the innate immune system and acquire cytotoxic potential during development, 
adaptive CD8+ T cells differentiate into cytotoxic effectors upon engagement of MHC class I 
molecules with cognate antigen in the context of cytokine stimulation during infections. 
In addition to target cell killing, cytotoxic lymphocytes can produce the pro-inflammatory 
cytokines interferon γ (IFN-γ) and tumor necrosis factor (TNF) as well as chemokines such as 
macrophage inflammatory protein-1β (MIP-1β) [3]. IFN-γ has anti-viral, anti-mycobacterial and 
growth inhibitory properties and promotes MHC class I/II expression as well as T-helper 1 
differentiation [4]. TNF stimulates the release of other pro-inflammatory mediators, facilitates 
recruitment and maturation of myeloid cells, and has direct cytotoxic effects [5]. MIP-1β mainly 
functions to mobilize other innate and adaptive inflammatory cells to sites of injury or infection 
[6]. 
This thesis aims to expand our understanding of cytotoxic lymphocyte differentiation 
processes, how such processes contribute to protecting the host from infection and how 
imbalances in these processes may cause disease. This could help in developing tools to 
manipulate or harness cytotoxic lymphocyte responses in chronic infection, autoimmune 
disorders and cancer. 
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1.1.1 NK Cells 
Today, NK cells are considered part of a larger group of innate lymphoid cells (ILCs) 
characterized by the lack of somatically recombined antigen receptors found on adaptive B and 
T cells. While NK cells mediate cytotoxicity, the other ILCs are grouped according to their 
cytokine-mediated roles in immune responses against pathogens and formation of secondary 
lymphoid tissues [7,8]. 
NK cells constitute 5-15% of peripheral blood mononuclear cells (PBMCs) and were first 
described in mice in 1975 by two independent laboratories at the Karolinska Institutet, 
Stockholm and the National Institutes of Health, Bethesda [9,10]. Kiessling et al. and 
Herberman et al. reported large granular lymphocytes isolated from spleen and other lymphoid 
organs with the ability to rapidly kill leukemia and tumor cells in culture without prior 
sensitization within one to four hours. Shortly after, first evidence for a central role of MHC 
class I in NK cell-mediated target cell recognition resulting in bone marrow and tumor graft 
rejection emerged [11]. Klas Kärre and colleagues finally proposed an alternative, more 
primitive immune defense strategy complementary to T cells, which was based on NK cell 
detection of MHC class I levels on aberrant or foreign cells [12]. This “missing-self” hypothesis 
stipulated that NK cell activation occurs upon absence or reduced expression of self-MHC 
class I, in contrast to cytotoxic T cells which rely on TCR-mediated recognition of peptides 
presented by MHC class I. Down-regulation of MHC class I poses a powerful immune evasion 
strategy employed by viruses and tumor cells to avoid T cell-mediated destruction. Therefore, 
detection of missing or reduced MHC class I by NK cells serves to discriminate between self 
and non-self and complements adaptive immunity.  
Today, the concept of “missing-self” is well established and many of the receptors binding 
MHC class I have been discovered. In an example of convergent evolution, mouse NK cells 
express inhibitory Ly49 receptors for detection of MHC [13] while human NK cells sense MHC 
quality and quantity largely via the family of inhibitory killer cell immunoglobulin-like receptors 
(KIRs) [14]. A multitude of mostly uniformly expressed, germline-encoded activating receptors 
that bind stress-induced ligands or ligands indicating “self” complement the inhibitory receptors 
in target cell recognition. Thus, the lack of inhibitory or an increase in activating signals 
promotes NK cell activation. More recently, inhibitory receptors have been implicated in a 
process termed “education” or “licensing” [15,16], which tunes NK cell reactivity depending on 
the net signaling strength generated during sub-threshold interactions with healthy cells [17]. 
This ultimately results in a spectrum of activation thresholds determined by the combination of 
activating and inhibitory receptors on a given NK cell and the ligands expressed on the surface 
of the other host cells at steady-state [18–20]. 
Besides their function as innate killers in early defense against viruses and cancer, NK cells 
rapidly produce large amounts of IFN-γ, TNF and MIP-1β, thereby instructing and shaping the 
immune response (see above). NK cells also relay signals from other immune cells by 
producing IFN-γ in response to combinations of exogenous cytokines such as interleukin (IL)-
12, IL-15, IL-18 and IFN-α [21]. Importantly, immunoregulatory killing of activated immune cells 
by NK cells is vital to maintain immune homeostasis as evidenced by primary 
immunodeficiencies (PIDs) such as familial hemophagocytic lymphohistiocytosis (FHL), 
caused by genetic defects in lymphocyte cytotoxicity [22,23]. Furthermore, the innate 
functionality of NK cells is harnessed to mediate graft-versus-leukemia (GvL) effects in settings 
of hematopoietic stem cell transplantation and cancer immunotherapy [24]. 
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Since their discovery more than 40 years ago, many fundamental aspects of NK cell biology 
such as modes of activation and target cell recognition have been uncovered. Furthermore, an 
impressive body of work has been accumulated describing the origin and development of early 
NK cell progenitors as well as the differentiation into diverse, unique repertoires of mature NK 
cell subsets that can by found in circulation and various peripheral tissues. Importantly, the 
idea of NK cells as strictly innate effectors has been challenged. Recent findings ascribe 
features of immunological memory to specialized NK cell subsets after exposure to pathogens, 
in particular cytomegalovirus (CMV). 
NK cell receptors and signaling 
In contrast to T and B cells, which are largely governed by a single, somatically recombined 
antigen receptor, NK cell function is determined by the sum of signals provided by an array of 
germline-encoded activating and inhibitory surface receptors. While most activating receptors 
are uniformly expressed on mature NK cells, expression of inhibitory receptors appears 
stochastically distributed and changes upon terminal differentiation [25]. Importantly, with the 
exception of CD16, most activating NK cell receptors are “co-activating” or “co-stimulatory” in 
nature. Insufficient to trigger effector functions in freshly isolated, resting NK cells by 
themselves, co-engagement of at least pairwise combinations of receptors is required for 
cytokine production and degranluation [26]. The molecular basis for such receptor synergy has 
recently been uncovered and co-stimulation is needed to overcome a threshold for Vav1 
activation set by the E3 ubiquitin ligase c-Cbl [27,28]. Furthermore, the signals for cytolytic 
granule exocytosis and polarization are uncoupled. Engagement of the β2 integrin LFA-1 by 
ICAM-1 is necessary for granule polarization and directed release to facilitate target cell lysis 
with minimal killing of bystander cells [29,30]. 
The majority of inhibitory NK cell receptors expressed at steady-state bind classical or non-
classical MHC class I molecules found on all nucleated healthy human cells in a non-peptide 
specific manner [31]. As MHC class I alleles may or may not be expressed in a given individual 
and inhibitory receptor expression on NK cells is variegated, tolerance is ensured by 
“disarming” cells that do not possess receptors for self-MHC. In contrast, NK cells expressing 
self-binding inhibitory receptors become “educated” or “licensed” to produce cytokines and 
degranulate against target cells with reduced MHC class I surface levels as a result of 
infection, transformation or stress [18,19]. While the concept of NK cell education is well 
established, the underlying molecular and cellular mechanisms are still incompletely 
understood. Guia et al. proposed that tonic inhibitory signals promote the reorganization of 
activating receptors into membrane nanodomains necessary for full NK cell reactivity [32]. 
Moreover, very recent data suggest a role for higher basal activity of the mTOR/Akt pathway 
that correlates with the number of inhibitory receptors on educated murine NK cells [33]. 
The most prominent inhibitory receptors expressed by human NK cells are members of the 
large family of inhibitory killer cell immunoglobulin-like receptors (KIRs), NKG2A and LILRB1 
(CD85j). Inhibitory KIRs bind alleles of the classical MHC class I molecules HLA-A, B or C [14] 
and are mostly expressed at later stages of mature NK cell differentiation as discussed further 
below. In contrast, the inhibitory receptor NKG2A, which localizes to the cell surface as a 
heterodimer with CD94, is mostly found on earlier stages of NK cell maturation and binds the 
non-classical MHC class I molecule HLA-E [34–36]. Stabilized by leader peptides of classical 
MHC class I molecules, HLA-E levels depend on peptide availability and NKG2A therefore 
senses MHC class I expression indirectly [37]. Inhibitory CD85j is mostly found on terminally 
differentiated NK cells and, except for its high affinity ligand HLA-G, binds to a broad variety of 
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classical and non-classical MHC class I molecules with lower affinity compared to inhibitory 
KIRs or NKG2A. 
Inhibition by the receptors above is mediated by one or several immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) in their cytoplasmic tails. Src-family kinases such as Lck 
phosphorylate the central tyrosine of an ITIM upon receptor engagement, leading to 
recruitment of phosphotyrosine phosphatases SHP-1 and SHP-2 via their tandem SH2-
domains [38]. These negative regulators intercept early activating signals, probably by 
dephosphorylating Src- and SYK-family kinases, although this still remains to be shown in 
primary human NK cells. In fact, only the guanine nucleotide exchange factor Vav1, a regulator 
of the actin cytoskeleton, has been identified as SHP-1 substrate after NK cell co-culture with 
HLA-C expressing target cells [39]. Dephosphorylation of Vav1 after inhibitory receptor 
engagement likely blocks re-organization of the actin mesh, thereby obstructing formation of a 
stable immune synapse as well as recruitment and clustering of activating receptors [31,40–
42]. Concomitantly, inhibitory receptors have also been shown to trigger phosphorylation of the 
signaling adaptor Crk by the tyrosine kinase c-Abl, resulting in dissociation of the signaling 
complex regulating actin re-organization [43]. 
A portion of activating NK cells receptors possess only small intracellular domains and couple 
to immunotyrosine-based activation motif (ITAM)-containing adaptor molecules for signaling. 
CD16 and the natural cytotoxicity receptors (NCRs) NKp30 and NKp46 can form complexes 
with homo- as well as heterodimers of FcεRγ or CD3ζ. In contrast, NKG2C and activating KIRs 
as well as the NCR NKp44, which is expressed on IL-2 activated peripheral blood and resting 
uterine NK cells, couple to DAP12 homodimers [44–46]. The low affinity Fc-receptor CD16 
(FcγRIIIa) can be found on the majority of human peripheral blood NK cells and allows for the 
destruction of IgG opsonized target cells by antibody-dependent cellular cytotoxicity (ADCC) 
[47]. As CD16 function depends on adaptive B cell responses the receptor is not considered to 
confer natural cytotoxicity, which per definition relies entirely on innate receptor-ligand pairs. In 
contrast, the NCRs NKp30, NKp44 and NKp46 bind a variety of known and unknown cellular 
as well as viral and bacterial ligands on transformed or infected cells [48]. Importantly, the 
NKp30 agonist B7-H6 is expressed on many tumor cell lines and is induced on monocytes and 
neutrophils upon stimulation with TLR-ligands or pro-inflammatory cytokines [49,50]. NKp30 
thus not only plays a role in immunosurveillance of infected and transformed cells but also 
contributes to immunoregulation of activated immune cells. Similar to its inhibitory counterpart, 
NKG2C is expressed as heterodimer with CD94 and binds the non-classical MHC class I 
molecule HLA-E [35,36]. NKG2C therefore has an important function in sensing virus infection 
via reduced MHC class I but stabilized or elevated HLA-E levels, an immune evasion strategy 
adopted by for instance HCMV, HCV and HIV [51–53]. Despite the similarities of inhibitory and 
activating KIRs as a result of gene duplication, only some activating KIRs have been shown to 
bind MHC class I molecules with low affinity and ligands for the majority of receptors remain 
unknown [46]. Thus, the precise role of activating KIRs in NK cell biology still needs to be 
uncovered. Similar to ITIMs, the central tyrosine-residues of ITAMs get phosphorylated by Src-
family kinases upon receptor engagement, which results in recruitment of SYK-family kinases 
SYK or ZAP-70. These phosphorylate the scaffold proteins LAT and SLP-76 as well as other 
signaling molecules downstream, ultimately leading to influx of Ca2+ ions from the extracellular 
space and activation of central regulators of NK cell function. These include the MAP kinases 
ERK and p38 as well as the transcription factors NFκB and NFAT [54,55]. 
Among others, important non-ITAM-coupled activating receptors on resting NK cells include 
NKG2D (CD314), members of the SLAM-family of receptors (SLAMFRs) and DNAM-1 
(CD226). NKG2D binds to stress ligands induced by infection, transformation or DNA damage 
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and plays a prominent role in cancer surveillance, as NKG2D-deficient mice are more likely to 
develop spontaneous tumors [56]. NKG2D-ligands include the MHC class I-like molecules 
MICA and MICB as well as members of the ULBP family [57]. NKG2D couples to the 
transmembrane adaptor protein DAP10 [58], which is able to recruit either the p85 subunit of 
PI3K or a Grb2-Vav1 complex for NK cell activation and cytotoxicity [59–62]. 
SLAMFRs are broadly expressed on hematopoietic cells and, with the exception of 2B4 
(CD244) which binds CD48, form homophilic interactions in trans [63]. Resting NK cells 
express the SLAMFRs CD84, Ly9 (CD229), 2B4 (CD244), CRACC (CD319), and NTB-A 
(CD352). SLAMFRs possess immunoreceptor tyrosine-based switch motifs (ITSMs) within 
their cytoplasmic tail and can bind positive or negative regulators of cell signaling. The small 
SAP-adaptors SAP and EAT-2 propagate activating signals by recruiting the Src-family kinase 
Fyn or the phospholipases PLCγ1 and PLCγ2, respectively [63–66]. Additionally, SAP-
adaptors prevent binding of negative regulators of cell signaling such as SHP-1, SHP-2, SHIP 
and Csk to the ITSM [67]. Importantly, genetic defects in SH2D1A encoding SAP underlie X-
linked lymphoproliferative disease type I (XLP1). Characterized by defects in T and NK function 
and hyperinflammation, XLP1 underscores the importance of regulating activated immune cells 
to prevent pathology [68,69]. Recently, the inhibitory potential of SLAMFRs has also been 
shown to contribute to NK cell education in mice and XLP1 patients [70,71]. 
Similar to NKG2D, the receptor DNAM-1 prevents spontaneous tumor formation and tumor 
growth in mice [72] and has a critical role in NK recognition and killing of freshly isolated human 
cancer cells [73–75]. DNAM-1 binds the nectin adhesion molecule CD112 and the poliovirus 
receptor CD155, which are upregulated on tumors but also activated dendritic and T cells [76–
78]. Interestingly, DNAM-1 physically and functionally associates with the β2 integrin LFA-1 
and DNAM-1 surface levels on a given NK cell positively correlate with the quality and quantity 
of educating signals provided by inhibitory receptors for self [79,80]. The cytoplasmic domain of 
DNAM-1 was recently shown to recruit the adaptor Grb2 via an ITT-like motif. This was 
sufficient to activate of Vav1, PI3K and PLCγ1 as well as promote activation of Erk, Akt and 
calcium influx downstream [81]. 
Curiously, NK cells express seemingly redundant pairs of signaling molecules and adaptors of 
which individual members are usually associated with specific hematopoietic lineages. While 
FcεRγ, SYK and PLCγ2 are typically expressed in B- or myeloid cells, CD3ζ, ZAP-70 and high 
levels of PLCγ1 are restricted to T cells. Despite some evidence for PLCγ isoform preference 
downstream of specific NK cell receptors [82], results obtained from PLCγ2 deficient mice and 
humans with PLCγ2 mutations suggest a central role for PLCγ2 in NK cell function [83,84]. In 
contrast, SYK or ZAP-70 alone are sufficient for signaling downstream of ITAMs but show 
differences in dependency on upstream Src-family kinases [85]. A somewhat unique pair, the 
SAP-family adaptors SAP and EAT-2 have distinct roles in recruiting different signaling 
molecules to SLAMFRs. In humans and mice, SAP is found in T cells while EAT-2 appears to 
be NK cell specific although low expression can be detected in murine macrophages and 
dendritic cells [86]. This NK cell specific profile of SAP family adaptors suggests a unique role 
for SLAMFRs in NK cell biology and function, in particular regarding surveillance of 
hematopoietic cells [87]. Overall, the reason for pairwise expression of signaling proteins in NK 
cells compared to other lineages remains to be elucidated. We hypothesized that differential 
expression of signaling molecules upon NK cell differentiation may provide an additional layer 
of regulation and means of functional diversification (paper II).  
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NK Cell Development 
As lymphocytes, NK cells develop from CD34+ hematopoietic stem cells (HSCs) and bone 
marrow as a source of NK cell progenitors was first postulated shortly after their discovery [88]. 
To determine a more specific NK cell progenitor, mature human NK cells were later generated 
from CD34+HLA-DR– and CD34+CD7+ cells isolated from bone marrow [89,90], from 
CD34+CD3–CD4–CD8– fetal thymocytes with NK and T cell potential [91] as well as from 
CD34+CD38+ fetal liver cells without T cell potential [92]. Using additional surface markers such 
as CD56, CD16, CD94, CD7 and NKR-P1A (CD161) Jaleco et al. proposed a model for NK 
cell development based on their findings in fetal liver. This was later expanded and refined by 
Freud and colleagues in the laboratory of Michael Caligiuri investigating human bone marrow, 
lymph nodes and tonsils [93–95]. The model by Freud et al. describes five discrete stages of 
human NK cell development from CD34+CD45RA+ bone marrow precursors in secondary 
lymphoid tissues. There, progenitors undergo progressive NK cell commitment as a result of 
cues provided by the local environment. IL-15 in particular has been shown to be instrumental 
for NK cell development [96] and mutations in the IL-15 receptor affecting the common γ-chain 
CD132, the IL-2R/IL-15Rβ chain CD122 or defects in the signaling molecule JAK3 downstream 
of the IL-15 receptor manifest in severe combined immunodeficiency with loss of NK cells [97–
100]. While the developmental stages 1-3 contain early progenitors and immature NK cells, 
stage 4 and stage 5 are considered mature, functional NK cells. 
With the discovery of other, non-cytotoxic ILC subsets the search for a committed NK cell 
precursor without ILC potential shifted into focus as considerable overlap between NK cell and 
ILC developmental stages and sites exist [101]. Recently, an early NK cell-lineage restricted 
progenitor without ILC potential was identified in fetal and adult tissues [102]. Furthermore, 
Freud et al. provided an updated view of NK/ILC development by introducing the 
developmental stages 4a and 4b, defined by expression of the surface receptor NKp80 [103]. 
Stage 4b NKp80+ were cytotoxic and expressed higher levels of T-bet and EOMES. In mice, T-
bet and Eomes control central checkpoints of NK cell maturation [104] and cooperatively 
induce high expression of CD122. This allows for IL-2/15 responsiveness important for 
development of effector functions and survival [104,105]. In contrast, stage 4a NKp80– cells 
produced IL-22 and expressed higher levels of ILC3-associated transcription factors [103]. 
NK Cell Differentiation and Function 
Mature stage 4 and 5 NK cells in peripheral blood and secondary lymphoid organs can be 
identified by differential surface expression of the neural cell adhesion molecule (NCAM) CD56 
and the low affinity Fcγ-receptor CD16 while uniformly lacking T cell-associated CD3 [106,107]. 
Simplified, stage 4 cells are CD56brightCD16–, while stage 5 is characterized by a CD56dim and 
mostly CD16+ phenotype. The existence of intermediate phenotypes led to the proposal that 
CD56dim derive from CD56bright NK cells. Indeed, different laboratories provided evidence for 
shorter telomere length in CD56bright compared to CD56dim cells as well as the potential of 
CD56brightCD16– cells to upregulate perforin and CD16 and to differentiate into CD56dimCD16+ 
NK cells upon in vitro activation or transfer into NOD-SCID mice [108–111]. Furthermore, 
CD56bright NK cells are among the first lymphocytes to repopulate after hematopoietic stem cell 
or umbilical cord blood transplantation and acquire CD16 expression and increased cytolytic 
function over time [112–114]. 
Approximately 10% of peripheral blood NK cells are CD56bright, while this ratio is reversed in 
lymph nodes and tonsils. CD56bright cells uniformly express the secondary lymphoid tissue 
homing markers CCR7 and CD62L, whereas CD56dim NK cells lack CCR7 and show 
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variegated CD62L expression [21,115,116]. Functionally, CD56bright NK cells are considered 
mostly immunoregulatory, producing larger amounts of IFN-γ and other soluble factors than 
CD56dim cells upon stimulation with combinations of monocyte-derived cytokines such as IL-12, 
IL-15, IL-18 and IL-1β [116]. They express lower levels of the cytotoxic molecules perforin and 
granzymes and less efficiently form conjugates with susceptible targets cells [117]. 
Furthermore, as they lack expression of inhibitory KIRs but uniformly express NKG2A, 
CD56bright NK cells are less well equipped to perform immunosurveillance of virus-infected cells. 
In line with this notion, the lack of CD16 also renders them incapable of antibody-dependent 
cellular cytotoxicity (ADCC) of infected cells. 
While CD56bright NK cells constitute a relatively homogeneous population, peripheral blood 
CD56dim NK cells display much more diverse phenotypes as a result of continued differentiation 
leading to differences and specialization regarding function, target cell recognition and 
activation thresholds. The expression of CD62L on CD56dim NK cells has been associated with 
a functionally intermediate stage characterized by abundant IFN-γ production and proliferative 
capacity after cytokine stimulation as well as strong natural and antibody-dependent 
cytotoxicity and cytokine production after stimulation with susceptible target cells [118]. 
Furthermore, three independent labs described the terminal differentiation of CD56dim NK cells 
based on loss of NKG2A but acquisition of KIR and CD57 expression [114,119,120]. 
Differentiation along this axis is accompanied by gradual loss of proliferative capacity and 
IFN-γ production after IL-12+IL-18 stimulation while expression of cytotoxic granule constituent 
as well as target cell killing, degranulation and cytokine production after CD16 engagement 
increase. Terminal differentiation of CD56dim NK cells thus seems to direct NK cell function 
towards immunosurveillance of infected cells. Importantly, differentiating cells also acquire 
expression of the receptor NKG2C and the ability to respond to HLA-E expressing target cells 
[114]. Recently, “memory-like” features of NKG2C+ NK cells as an adaptation to CMV infection 
have increasingly become the focus of interest and will be discussed in more detail in the next 
section and papers II-IV. 
Further highlighting the heterogeneity of mature NK cells, phenotypically and functionally 
distinct tissue-resident NK cells can be found in the liver and female reproductive tract, where 
they aid in pathogen surveillance or regulate placentation, respectively [121–123]. 
Adaptive NK cells 
Herpesviruses such as herpes simplex viruses (HSV) type 1 and 2, Epstein Barr Virus (EBV) 
or Cytomegalovirus (CMV) are ubiquitous in nature and establish life-long latent infections with 
opportunistic reactivation in large proportions of people in all parts of the world. While infections 
in the healthy are often asymptomatic and go unnoticed, newborns and immunocompromised 
individuals unable to control the viruses may develop severe and potentially lethal pathology. 
Herpesviruses have co-evolved with their hosts for millions of years and have developed 
mechanisms to avoid detection and clearance by the immune system [124]. Cytomegalovirus 
in particular devotes a vast number of genes to manipulate and evade the immune response 
[125]. In return, the human innate as well as adaptive immune system have developed 
countermeasures to keep these infections in check. NK cells appear at the center of controlling 
herpesvirus infections [126] and primary immunodeficiencies (PIDs) marked by NK cell loss or 
dysfunction result in susceptibility to herpesviruses in man [127,128]. Surprisingly, in the 
absence of T cells, NK cells alone can be sufficient to confer protection from lethal CMV 
infection as evidenced by a patient with mutations in the IL-7 receptor α chain resulting in a T–
B+NK+ SCID [129]. Notably, the vast majority of NK cells detected in this case study were 
NKG2C+. 
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In mice (C57BL/6), NK cells expressing the activating, DAP12-couple receptor Ly49H expand 
up to 1000-fold and persist after a contraction phase for several months following MCMV 
infection [130–134]. Theses cells display increased IFN-γ production and degranulation after 
re-challenge and confer protection from MCMV upon adoptive transfer into naïve mice [134]. 
Ly49H directly binds the virus-encoded protein m157 [135,136] and m157-deficient mutants fail 
to induce expansion and memory-like responses [134]. 
Evidence for a similar role of NKG2C+ NK cells in detection of HCMV infection first arose after 
phenotyping PBMCs from healthy CMV+ or CMV– donors and aviremic HIV+ individuals 
[137,138]. In these studies, Guma et al. could show that seropositivity for CMV but not other 
members of the herpesvirus family correlated with temporally stable increases in frequencies of 
NKG2C+ NK cells. Of note, Guma et al. also reported decreased surface expression of CD161 
as well as the NCRs NKp30 and NKp46, while frequencies of inhibitory KIRs and CD85j+ cells 
were elevated in CMV+ donors. Shortly after, the same group demonstrated that fibroblasts 
actively infected with CMV could trigger expansion of NKG2C+ NK cells in vitro when co-
cultured in the presence of IL-15 [139]. This effect was inhibited by addition of anti-CD94 
antibodies during co-culture, supporting the notion of a direct involvement of the CD94/NKG2C 
dimer in sensing acute CMV infection. This was followed by findings in patients undergoing 
solid organ or hematopoietic stem cell transplantation [140,141]. CMV reactivation in these 
patients led to stable expansions of differentiated, CD57+NKG2C+ NK cells with increased 
potential to produce IFN-γ compared to NKG2C– cells, implicating a functional adaptation after 
pathogen exposure in vivo. Indeed, evidence for epigenetic changes by demethylation of the 
IFNG locus was later shown to be at least partially responsible for the increase in cytokine 
production in NKG2C+ NK cells after CMV infection [142]. Of note, expansions of NKG2C+ NK 
cells have also been described in individuals with acute Hantavirus [143] and chronic Hepatitis 
B or C virus [144] infections, but only occurred in CMV+ patients, underlining the central role of 
CMV for their development. 
While murine “memory-like” NK cell properties have mostly been ascribed to the Ly49H+ 
compartment [134], human “adaptive” NK cells appear to be more diverse. NK cells co-
expressing DAP12-coupled activating KIRs and inhibitory self-KIRs besides NKG2C were 
shown to expand and persist in CMV+ donors [145]. At roughly the same time, the group of 
Sungjin Kim reported elevated frequencies of NK cells lacking expression of the intracellular 
signaling adaptor FcεRγ in CMV+ individuals [146,147]. These cells displayed greatly increased 
cytokine responses when stimulated with anti-CD16 antibodies or when co-cultured with 
HCMV or HSV-1 infected target cells in the presence of serum containing virus-specific 
antibodies [146–148]. In contrast, FcεRγ– NK cells responded poorly to tumor targets, 
indicating a special role in recognition of virus-infected cells. FcεRγ– NK cells also expressed 
elevated levels of anti-apoptotic Bcl-2 and cell frequencies were stable over time for up to nine 
months, supporting the notion of memory-like behavior of these cells. Importantly, FcεRγ– NK 
cells uniformly showed decreased expression of NKp30 and NKp46 but were not entirely 
contained within the NKG2C+ population, emphasizing the potential diversity of human 
adaptive NK cells (Figure 1). 
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Figure 1. Phenotypic and functional characteristics of human adaptive NK cells. CMV-associated 
adaptive NK cells often express DAP12-coupled NKG2C or activating KIRs and inhibitory receptors 
for self-MHC Class I (self-KIR). Compared to canonical “stage 5” CD56dim NK cells, adaptive NK 
cells uniformly express high levels of CD85j and CD2 while downregulating CD161, CD7, Siglec-7, 
NKp30 and NKp46 surface expression as well as expression of the intracellular signaling adapter 
FcεRγ. Functionally, adaptive NK cells display increased cytokine production upon CD16 stimulation 
compared to canonical CD56dim NK cells, which can at least partially be explained by 
hypomethylation of the IFNG locus. Elevated expression of Bcl-2 may facilitate long-term survival 
similar to memory T cells. 
 
The origin and the precise instructive signals for the development and survival of human 
adaptive NK cells remain largely unknown. In Nfil3-deficient mice lacking conventional NK 
cells, MCMV infection drives the development and expansion of Ly49H+ NK cells with memory 
features in an m157-dependent manner similar to wildtype (WT) mice [149]. Blocking IL-12 
and/or type I IFN signaling with monoclonal antibodies prevented formation of the memory 
pool, indicating a critical role for pro-inflammatory cytokines in this process. Similarly to WT 
cells, memory-like NK cells were dependent on IL-15 signaling for homeostasis and survival 
[149].  In a follow-up study, Beaulieu et al. found that the transcription factor Zbtb32 was highly 
upregulated early during viral infection [150]. Responsible for the proliferative burst but not 
survival of Ly49H+ NK cells, expression of Zbtb32 was induced by IL-12, IL-18 and type I IFN 
signaling leading to STAT4 activation and binding to the Zbtb32 promoter. Mechanistically, 
Zbtb32 antagonized the anti-proliferative transcription factor Blimp-1 allowing for the expansion 
of virus-specific NK cells. In line with these observations, Rölle et al. could demonstrate a 
similar role for monocyte-derived IL-12 in the expansion of human NKG2C+ NK cells when co-
cultured with CMV infected fibroblasts. Blockade of either IL-12 or CD94/NKG2C signaling 
significantly inhibited the proliferation of NKG2C+ cells [151]. In mice, engagement of DNAM-1 
during MCMV infection also poses a requirement for the differentiation of memory-like NK cells 
[152] but a role for DNAM-1 in human adaptive NK cell differentiation remains to be 
demonstrated. 
Although the phenotypic and functional heterogeneity of human NK cells were well 
appreciated, deeper insights into the potential diversity of adaptive NK cell responsiveness as 
well as surface receptor and signaling molecule expression were lacking. We thus set out to 
investigate the phenotypic, functional as well as molecular changes that accompany NK cell 
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differentiation in response to CMV infection (paper II). Furthermore, we addressed the aspect 
of adaptive NK cell longevity by utilizing peripheral blood samples form patients with 
heterozygous mutations in GATA2 (paper III) as well as individuals with paroxysmal nocturnal 
hemoglobinuria (PNH) (paper IV). 
GATA2 encodes the transcription factor GATA-binding protein-2 (GATA-2) required for 
survival, homeostasis and proliferation of hematopoietic stem and progenitor cells (HSPCs) 
[153,154]. Importantly, GATA-2 haploinsufficiency as a result of heterozygous loss-of-function 
mutations in GATA2 can manifest in hypocellular bone marrow failure and immunodeficiency 
with progressive loss of monocytes, DCs, B and NK cells [155,156]. Patients may thus develop 
severe mycobacterial, papilloma and herpes virus infections [157,158], but also present with 
myelodysplastic syndrome (MDS) that can evolve to acute myeloid leukemia (AML) [159–162]. 
Curiously, while GATA2 deficiency is associated with loss of immature CD56bright NK cells, 
some patients accumulate terminally differentiated CD56dim NK cells [163,164]. We thus 
speculated that NK cells in these patients represent long-lived adaptive NK cells that persist 
after attrition of the stem cell pool. To this end, we performed extensive phenotypic and 
functional analysis of NK cells in GATA2 patients and asymptomatic carriers (paper III). 
Employing a similar strategy to investigate adaptive NK cell homeostasis and survival, we 
examined PBMCs from patients with PNH caused by acquired loss-of-function mutations of 
PIGA in HSPCs [165]. As PIGA encodes phosphatidylinositol N-acetylglucosaminyltransferase 
subunit A, a critical component of the synthesis pathway of glycosylphosphatidylinositol (GPI) 
anchors, patients produce mature hematopoietic cells without GPI-anchored membrane 
proteins. GPI+ and GPI– HSPCs may co-exist in the bone marrow and produce progeny for 
years giving rise to mixed phenotypes of peripheral blood cell populations. For unknown 
reasons, GPI– HSPCs may progressively and completely dominate replenishment of lineages 
with shorter half-lives such as neutrophils and red blood cells. T cell lineages largely maintain 
GPI+, likely a result of homeostatic self-renewal of mature cells in the periphery. We 
hypothesized that potentially long-lived adaptive NK cells would retain GPI-anchors while 
canonical NK cells with an estimated half-life of 14 days [166] originate from GPI– HSPCs. 
Therefore, we used adaptive NK cell markers established in paper II in combination with 
stainings for GPI-anchors to determined the distribution of canonical and adaptive NK cell 
populations within GPI+ and GPI– subsets in PNH patients (paper IV).  
 
1.1.2 T cells 
Together with antibody-producing B cells, T cells belong to the adaptive arm of the vertebrate 
immune system. They are characterized by antigen specificity and the ability to form memory 
cells, which mount rapid responses upon pathogen re-challenge. Antigen specificity and T cell 
activation are dictated by somatically recombined, clonally distributed T cell receptors (TCR) 
that recognize foreign peptides presented by MHC molecules on the surface of antigen 
presenting or target cells. The TCR is a heterodimer of either αβ- or γδ-chains encoded by 
TCRA and TCRB or TCRG and TCRD loci, respectively. The TCR propagates intracellular 
signals via ITAM-containing CD3 adaptors, in particular CD3ζ, within the TCR-complex. 
Constituting approximately 95% of total T cells, the two most abundant subsets use αβTCRs 
and can be distinguished by surface expression of the co-receptors CD4 and CD8 [167,168]. 
CD4+ T helper (TH) cells recognize peptides in the context of MHC class II on professional 
antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages, and 
differentiate into potent cytokine producers to instruct and orchestrate the immune response 
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[169]. CD8+ T cells sense foreign peptides presented by MHC class I molecules, which are 
expressed on all healthy cells of the body except for red blood cells. Upon activation in 
secondary lymphoid organs, mature but antigen-inexperienced (“naïve”) CD8+ T cells 
proliferate and differentiate into effector cells with the potential to kill infected or neoplastic cells 
and produce IFN-γ and TNF. The stages of CD8+ T cell development and differentiation into 
cytotoxic effector and memory cells will be discussed in more detail below. 
T cell development 
T cell precursors develop from common lymphoid progenitors in the bone marrow and migrate 
to the thymus where they mature into different T cell lineages. Crucial checkpoints during these 
processes involve the recombination of TCR genes and selection of T cell clones on thymic 
epithelial cells. 
The incredible diversity of theoretically more than 1015 different human αβTCRs [170] is the 
result of combinatorial events linking one of multiple variable (V), diversity (D) and joining (J) 
segments of the TCR loci to produce V-D-J containing β-chains and V-J containing α-chains. 
Initially, recombination activating gene (RAG) 1 and 2 proteins expressed in CD4/CD8 double-
negative (DN) thymocytes introduce DNA breaks at recombination signal sequences (RSS) 
flanking the V, D and J regions. DNA looping and repair by non-homologous end joining 
ultimately yield recombined β-chains. Additional junctional diversity is introduced by terminal 
deoxynucleotidyl transferase (TdT) adding 1-10 nucleotides [171]. Successful recombination of 
the β-chains allows for the expression of a pre-TCR containing an invariant pre-Tα-chain on 
the cell surface. At this “β-checkpoint”, pre-TCR signaling results in a) “allelic exclusion” that 
silences the alternative β-chain allele, b) downregulation of RAG1/2 expression and c) several 
rounds of proliferation and progression to the CD4/CD8 double-positive (DP) stage. Re-
expression of RAG proteins in DP thymocytes facilitates the recombination of V and J regions 
of the α-chain and surface expression of a fully functional TCR. Importantly, failure to 
successfully recombine the TCR chains may lead to depletion from the thymocyte pool 
[172,173]. 
TCR+ CD4/CD8 DP cells are further selected on MHC molecules presenting self-peptides on 
thymic epithelial cells to establish tolerance (central tolerance) [174]. This process involves 
negative selection and elimination of TCRs that bind self-peptide–MHCs too strongly while 
clones that show low or medium affinities are positively selected and develop into naïve CD4 or 
CD8 single-positive (SP) T cells. In case of weak or absent interactions, cells undergo “death 
by neglect” (Starr 2003). As a result, only a fraction of possible V(D)J recombinations and thus 
unique TCRs actually contribute to the naïve T cell pool in vivo [175]. Nonetheless, it is safe to 
assume that any foreign peptide will be recognized more or less efficiently due to the cross-
reactive nature of most TCRs. While such cross-reactivity is thus a necessity to provide 
protective immunity, it is also a likely cause for autoimmune disorders [176]. 
The co-receptors CD4 and CD8 bind MHC class II or class I, respectively, and are crucial for 
commitment to the CD4 or CD8 SP lineage by recruiting the Src-family kinase Lck to the TCR 
complex allowing for signal initiation at the ITAMs. As a result, thymocytes bearing MHC class 
II specific TCRs develop into CD4+ T cells while MHC class I binding results in CD8+ T cell 
development [177]. Mature but naïve CD4 or CD8 SP T cells exit the thymus into circulation 
and can further differentiate into effector and memory cells upon activation in secondary 
lymphoid tissues. 
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CD8+ T cell differentiation 
CD8+ T cells acquire cytotoxic effector molecules and the potential to produce pro-
inflammatory cytokines upon further differentiation. Provided the appropriate signals and 
environmental cues, naïve cells proliferate extensively and generate short-lived effector as well 
as long-lived memory cells to protect from future insults by same pathogen.  
Dendritic cells play a central role in the initial steps of CD8+ T cell activation, proliferation and 
differentiation. Following infection, exposure of local DCs to PAMPs and pro-inflammatory 
cytokines such as IFN-γ lead to activation and maturation into a migratory phenotype. 
Expression of the chemokine receptor CCR7 allows activated DCs to enter lymphatic vessels 
and home to draining lymph nodes. Importantly, these DCs carry pathogen-derived peptides to 
lymph nodes where they are cross-presented on MHC class I to naïve CD8 T cells [178]. 
Besides TCR stimulation (signal 1), naïve T cells require CD28 co-receptor engagement 
(signal 2) by CD80/86 molecules on the surface of activated DCs as well as pro-inflammatory 
cytokines (signal 3) such as IL-12 or type I interferons for clonal expansion and differentiation 
[179–182]. Importantly, lack of co-stimulation results in T cell dysfunction and peripheral 
tolerance [183,184]. In mouse models of infection, T cell responses usually peak at 7-10 days 
post infection after which the majority of pathogen-specific cells die in a contraction phase 
leaving a small portion of memory cells [185]. These will respond rapidly and potently upon re-
challenge, quickly giving rise to large numbers of antigen-specific secondary effector cells. 
Based on functional and homing potential, mature T cells are categorized into undifferentiated 
naïve (TN), short-lived effector (TEFF) as well long-live effector memory (TEM) and central 
memory (TCM) cells [186,187]. Given the progressive nature of the differentiation process, 
these subsets have to be appreciated as states within a phenotypic and functional continuum 
[188,189]. Human CD8+ TN cells express high levels of the co-receptor CD28, the CD45RA 
isoform of the protein tyrosine phosphatase CD45, and the lymph node homing receptors 
CCR7 and CD62L. Specialized to fight pathogens at sites of infection, TEFF cells lack 
expression of CCR7 and CD62L as well as CD28, but show high expression of perforin and 
granzymes as well as the potential to produce large amounts of IFN-γ and TNF. Cytotoxicity 
and cytokine production positively correlate with surface expression of the carbohydrate 
modification CD57 [190–192], a marker for terminal differentiated or senescence cells with 
severely impaired proliferative capacity. Divided into central and effector memory populations, 
memory cells generally express the CD45RO splice variant. TCM cells express CCR7 and 
CD62L and thus have the potential to enter secondary lymphoid organs. They largely lack 
perforin and immediate effector function but show increased proliferative capacity compared to 
TEM cells, which are CCR7–CD62L– but often express perforin and rapidly produce IFN-γ upon 
stimulation [187,193,194]. Truly short-lived, proliferating TEFF as a result of infection can rarely 
be detected in peripheral blood from healthy donors. Instead, CD45RA+ effector memory cells 
(TEMRA) lacking CD28 and CCR7 expression are often used to study TEFF biology as they 
constitute potent killers and cytokine producers [186,193,194]. 
The STAT5-signaling cytokines IL-2, IL-7 and IL-15 occupy central roles in expansion, 
homeostasis and survival of CD8+ T cell subsets [195]. Shortly after activation, naïve cells 
transiently upregulate the high affinity IL-2Rα chain CD25, driving massive clonal expansion of 
antigen-specific cells by autocrine and CD4+ T cell-derived IL-2 [196]. Prolonged exposure to 
high concentrations of IL-2 also results in development of short-lived effector at the expense of 
memory cells [197,198]. Produced by activated DCs and macrophages, IL-15 also aids in 
clonal effector expansion and is crucial for survival and homeostatic proliferation of memory 
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cells [199–202]. Similarly, stroma cell-derived IL-7 supports naïve T cell homeostasis and 
memory T cell survival [202,203]. 
The precise mechanisms instructing effector versus memory differentiation are still 
incompletely understood. In mice, IL-12 levels during infection dictate the fate of effector cells 
by inducing expression of the transcription factor T-bet in a dose dependent manner [204]. 
High T-bet expression results in development of IL-7Rlow (CD127) short-lived effector cells 
(SLECs) while lower T-bet levels give rise to IL-7Rhi memory precursor effector cells (MPECs) 
[204–206]. In line with these observations, IL-12 has been demonstrated to regulate T-bet and 
Eomes levels after Listeria monocytogenes infection in mice to impose effector versus memory 
fates [207]. Similar to NK cells, both transcription factors are critical for CD8+ T cell 
differentiation, acquisition of effector functions and survival [105,208]. The transcription factor 
Blimp-1 also regulates terminal effector cell differentiation and cytotoxicity in CD8 T cells in 
mice. Blimp-1 deficiency results in impaired Gzmb expression and migration after influenza 
infection while, cytokine production and memory formation of virus-specific cells are normal 
[209]. Furthermore, Chang et al. proposed a model of effector versus memory fate decision 
based on asymmetric cell division shortly after initial activation [210]. They found that an 
unequal distribution of the surface receptors CD25, the signaling molecule PKC-ζ and T-bet 
during mitosis ultimately directed cells into different fates [210,211]. 
To cover the energetic and anabolic demands associated with effector and memory states, 
CD8+ T cells undergo substantial differentiation-dependent metabolic reprogramming [212]. 
Surprisingly, activated effector cells shift to anaerobic glycolysis for energy production. 
Although less efficient than catabolic, mitochondrial fatty acid oxidation (FAO) regarding ATP 
production, intermediates of anaerobic glycolysis are funneled into anabolic processes to 
provide the macromolecules required for proliferation and effector function [212,213]. In 
contrast, memory cells have large, fused mitochondria and show overall higher mitochondrial 
mass allowing for increased FAO and oxidative phosphorylation (OXPHOS) [214]. Important 
for development and survival, memory cells upregulate fatty acid and triglyceride synthesis as 
well as lysosomal lipolysis to fuel FAO and OXPHOS [214–216]. 
 
1.1.3 Tissue-resident memory T (TRM) cells 
T cell recall responses to re-infection are mediated by central and effector memory cell subsets 
with different functional and migratory properties (see above). The classical models describing 
memory T cell phenotypes and behavior are mostly based on observations made in peripheral 
blood and lymphoid tissues from where cells traffic to sites of inflammation in non-lymphoid 
tissues. This local immunity has thus been considered to be the result of activation, migration 
and differentiation of patrolling memory cells. Recently, it has become evident that distinct, 
antigen-specific memory T cells specialized for homing, persistence and homeostatic 
proliferation in non-lymphoid tissues are generated after infection [217,218]. These tissue-
resident T (TRM) cells provide superior local protection against pathogens at barrier tissues 
such as the skin [219], gut epithelium [220], lung [221,222] and the female reproductive tract 
[223,224], and have also been characterized in the brain [225] and liver [226,227]. While both 
CD4+ and CD8+ TRM subsets have been characterized, studies have mostly focused on 
investigating CD8+ TRM phenotype and function. 
The majority of non-recirculating TRM cells in peripheral tissues can be identified by surface 
expression of CD69, CD103 and CD49a, which promote tissue localization and retention [228–
231]. Although CD69 has classically served as a lymphocyte activation marker, it has also 
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been shown to negatively regulate sphingosine 1-phosphate receptor-1 (S1P1) function to 
prevent lymphocyte release into circulation [232]. Importantly, transcriptional downregulation of 
S1P1 is required to seed and establish CD8+ TRM cells in non-lymphoid tissues after infection 
[233]. As part of the heterodimeric integrin αEβ7, CD103 (integrin αE) binds to E-cadherin 
[234], which is broadly involved in the formation of adherens junctions between epithelial cells 
[235]. CD49a, the α1 subunit of the integrin α1β1, mediates adherence to the basement 
membrane at the epidermal-dermal interface via collagen IV [236,237]. CD49a was first 
described as very late antigen 1 (VLA-1) on cultured and activated T cells [238,239] and later 
shown to be expressed on a large proportion of T cells in arthritic joints while being absent on 
circulating T cells [240]. CD49a has been shown to facilitate tissue retention of lung resident T 
cell subsets following viral infection in both mice and humans [221,230,241,242].  
Importantly, the cytokine TGF-β has a central role in TRM cell formation and retention as it 
directly controls expression of CD103, CD69 and CD49a [231,243]. In combination with IL-33 
and TNF, TGF-β also downregulates expression of the transcription factor KLF2 and its 
downstream target S1P1, thereby promoting tissue retention [233]. Furthermore, co-expression 
of the related transcription factors Hobit and Blimp-1 in mice was recently shown to impose the 
transcriptional program that regulates anatomical localization by repressing genes mediating 
tissue egress [244]. Lastly, IL-15 has also been demonstrated to be crucial for TRM cell survival 
and homeostasis [243], similar to its effects on TCM and TEM populations in circulation. In 
addition, it also been proposed to act as danger signal driving TRM cell activation and effector 
function that can result in tissue destruction [245].  
CD8+ TRM cells in the skin 
The human skin serves as important barrier, protecting against injury and infection and is 
composed of the outermost epidermis and the dermis below. Multiple layers of keratinocytes in 
combination with melanocytes in the basal layer form the epidermis, which is divided from the 
dermis by a collagen-rich basement membrane at the epidermal-dermal junction. The dermis 
consists of connective tissue, fibroblasts and nerve fibers and is drained by blood and 
lymphatic vessels [246].  
Among human tissue samples, skin biopsies are comparatively easy to obtain and human 
cutaneous TRM cells are thus relatively well studied. In contrast to mice, αβT cells constitute the 
majority of human skin resident TRM cells in the epidermis and dermis [247]. Interestingly, 
human prenatal and newborn skin are mostly devoid of αβTRM cells [219,248], which are, 
similar to mice, likely generated upon pathogen challenge or colonization with commensal 
bacteria [249]. Indeed, virus-specific skin resident T cells can be detected in active and 
resolved herpes simplex virus 2 (HSV-2) and varicella zoster virus (VZV) lesions [250–252]. 
Human skin TRM cells express the inducible carbohydrate modification cutaneous lymphocyte-
associated antigen (CLA), which selectively facilitates P-selectin glycoprotein ligand-1 (PSGL-
1) binding of E-selectin [253]. While CLA can also be found on a small fraction of circulating T 
cells, the majority of CLA+ T cells home to the skin and co-express CCR4 and CCR6 as well as 
CCR8 and CXCR6 in a subset specific manner [254]. Cutaneous TRM cells display phenotypic 
properties of TEM cells and largely lack CD45RA and CD62L expression [254,255]. All skin 
resident human TRM cells express CD69 while CD103+ cells are enriched in the epidermis and 
display potent effector function but limited proliferative capacity compared to CD103– cells 
[219,255]. Importantly, although CD49a can be detected in healthy human skin [221], the 
distribution of CD49a expression on human TRM subsets and its functional implications are still 
incompletely mapped (Figure 2). 
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Figure 2. Phenotypic and 
migratory properties of circulating 
and skin-resident CD8+ T cell 
subsets. CD8+ TRM cells in skin 
largely display a TEM cell 
phenotype and uniformly express 
CD69 while expression of CD103 
and CD49 are more variable. TEM 
cells may circulate between 
lymphoid and non-lypmhoid 
tissues whereas naïve and TCM 
cells largely localize to the 
lymphatic system. TCZ, T cell 
zone; SLO, secondary lymphoid 
organ. Adapted from [217]. 
 
 
While local immune responses by TRM contribute to rapid and efficient pathogen containment, 
dysregulation may result in hyperinflammation and immunopathology as evidenced by spatially 
confined T cell-driven skin diseases such as psoriasis and vitiligo [256–258]. Psoriasis is 
characterized by hyperactivation and hyperproliferation of epidermal keratinocytes and 
cytokine-producing T lymphocytes. Lesions are maintained by cytokines of the IL-23/IL-17 axis 
and IL-22 producing CD4+ as well as IL-17 producing CD8+ TRM cells are enriched in the 
epidermis at sites of clinically healed psoriasis, forming a local disease memory [259]. In 
contrast, cytotoxic T cell-mediated destruction of melanocytes results in localized skin 
depigmentation observed in vitiligo [260]. CD8+ T cell-derived IFN-γ plays a central role in 
disease maintenance and progression in human patients and a vitiligo mouse model as it 
directly induces melanocyte apoptosis [261] and stimulates CXCL10 release promoting T cell 
recruitment into lesions [262,263]. 
To better understand the contribution of distinct skin-resident CD8+ TRM subsets to cytokine 
production and cytotoxicity, we set out to investigate the anatomical localization, transcriptional 
profiles and functional properties of CD8+ TRM cells in healthy as well as lesional skin from 
vitiligo and psoriasis patients (paper V). 
 
1.2 The cytotoxic machinery and immunodeficiency 
Despite the differences in target cell recognition, NK cells and CD8+ T cells largely employ the 
same cellular machinery to kill target cells by rapid, polarized release of specialized lysosome-
like organelles. Key cytotoxic proteins are stored in “secretory lysosomes” or “cytotoxic 
granules”, part of the endo-lysosomal system that sequentially mature by accumulating effector 
molecules via fusion of different vesicular structures, although the precise mechanisms are still 
incompletely understood [2]. 
Apart from lysosomal proteins and enzymes, cytotoxic granules contain proteins such as 
perforin and granzymes. Upon release, the multi-domain protein perforin attacks the target cell 
membrane in a Ca2+-dependent manner followed by pore formation via oligomerization 
[264,265]. Translated as a precursor in the ER, perforin is sorted into cytotoxic granules via the 
Golgi apparatus [266]. There, it is proteolytically cleaved by cathepsin L removing a 20 amino 
acid stretch at the very C-terminus necessary for full biological activity [267,268]. To prevent 
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activity within the lytic granules, perforin is inhibited by the acidic milieu as well as the proteins 
serglycin and calreticulin, which bind perforin directly or stabilize the granule membrane, 
respectively [269,270]. The transmembrane protein lysosome-associated membrane protein 1 
(LAMP-1 or CD107a) contributes to protecting the plasma membrane against perforin-
mediated attack after granule exocytosis [271]. Importantly, this also allows for flow cytometry-
based assessment of cytotoxic granule exocytosis by cell surface staining of CD107a 
[272,273]. 
Pore formation in the target cell membrane facilitates entry of other cytotoxic granule 
constituents, most importantly the serine proteases granzyme A and B. Granzymes reach the 
lytic granules as pro-enzymes and are processed by the protease cathepsin C and, in case of 
granzyme B, also cathepsin H [274–278]. In humans, five granzyme genes have been 
described [279]. While granzyme A and B appear constitutively expressed at high levels in NK 
cells and CTLs, the expression patterns of granzyme H, K and M are less well defined. 
Recently, high dimensional flow cytometry data comparing CD8+ T cell and NK cell subsets 
revealed an increase in expression of granzymes A, B and M throughout terminal 
differentiation while granzyme K was induced at early but downregulated at later differentiation 
stages [280]. Once delivered to the cytoplasm of a target cell, granzymes induce apoptosis by 
caspase-dependent and -independent pathways resulting in mitochondrial damage and 
generation of reactive oxygen species as well as DNA fragmentation [281]. Experiments in 
mice suggest central roles for granzyme A and B in target cell killing, as cell death mediated by 
cells isolated from GzmA/GzmB double-deficient mice was strongly reduced and delayed. 
Furthermore, granzyme B was significantly more efficient inducing apoptosis than granzyme A 
[282]. Interestingly, granzymes released into the extracellular space also have the potential to 
regulated pro-inflammatory cytokine production in other cell types [283]. Extracellular 
granzyme A in particular has been shown to stimulate IL-1β, TNF and IL-6 responses in human 
and murine monocytes [284]. 
Due to its destructive potential the release of lytic granules is tightly controlled. After initial 
contact, a stable but dynamic interaction between effector and susceptible target cell allowing 
for directed release of lytic granules is formed [285]. Structurally and functionally similar to its 
neuronal counterpart, this immunological synapse (IS) facilitates efficient killing without 
affecting bystander cells. The intracellular transport of lytic granules is highly dependent on the 
microtubule cytoskeleton. Upon contact formation, granules move in minus-end direction 
towards the microtubule-organizing center (MTOC) while it actively polarizes to the IS [286]. 
Now in close proximity to the IS, lytic granules are shuttled to the plasma membrane via 
anterograde transport on microtubules followed by membrane fusion and release of lytic 
granule contents into the synaptic cleft [287].  
Given the importance of lymphocyte cytotoxicity in pathogen defense and immune 
homeostasis, many processes and components governing lytic granule biology, trafficking and 
release have been uncovered by studying individuals with primary immunodeficiencies (PIDs) 
affecting target cell killing. Although disease manifestation and age of onset can differ 
depending on the type of mutation, genetic defects in lymphocyte cytotoxicity generally result in 
familial hemophagocytic lymphohistiocytosis (FHL), a life threatening hyperinflammatory 
condition often triggered by primary herpesviruses infection (Meeths 2014). Mutations in the 
genes encoding perforin (PRF1), Munc13-4 (UNC13D), syntaxin-11 (STX11) or StxBP2 
(UNC18B) are causative of FHL type 2-5, respectively [288–291]. Furthermore, mutations in 
RAB27A encoding the small GTPase Rab27a manifest in Griscelli syndrome type 2 (GS2), 
characterized by degranulation defects in cytotoxic lymphocytes and melanocytes [292]. Cells 
from individuals with perforin mutations can release lytic granules but fail to deliver granzymes 
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and induce target cell apoptosis. In contrast, Munc13-4, syntaxin-11, Munc18-2 and Rab27A 
are involved in granule trafficking, docking to and fusion with the plasma membrane. Munc13-4 
is deposited on perforin containing granules upon stimulation with activating receptors [293] 
and probably regulates interactions between vesicular SNARE (v-SNARE) and target 
membrane SNARE (t-SNARE) proteins, which provide the physical force for membrane fusion 
[2]. Rab27a is recruited to lytic granules upon LFA-1 stimulation [293] and facilitates docking to 
the plasma membrane [285]. Rab27a also interacts with Munc13-4, which has been shown to 
be crucial for plasma membrane tethering and fusion [294]. Related to classical t-SNAREs, 
Syntaxin-11 is deposited on the plasma membrane upon TCR stimulation of primary human 
CTLs [295] and probably mediates the final steps in subsequent membrane fusion and lytic 
granule exocytosis of cytotoxic lymphocytes as part of the SNARE complex. The SNARE 
accessory protein Munc18-2 interacts with syntaxin-11 and is vital for syntaxin-11 protein and 
possibly SNARE complex stability [291] (Figure 3). 
 
 
Figure 3. Simplified schematic of factors and events underlying lytic granule exocytosis. Rab27a and 
Munc13-4 mediate lytic granule trafficking and tethering to the plasma membrane at the immunological 
synapse (IS). Once in close proximity, SNARE proteins on granules (v-SNARE) and the plasma 
membrane (Stx11 and a Qbc-SNARE) can interact and form a four-helix bundle that facilitates 
membrane fusion, leading to release of the granule content and target cell killing. Besides trafficking 
and membrane tethering, Munc13-4 has also been implicated in promoting SNARE-complex formation. 
StxBP2 supports SNARE-complex stability and membrane fusion. Adapted from [296]. 
 
Importantly, the transcriptional and epigenetic regulation of factors vital for lytic granule 
exocytosis and their dynamics throughout cytotoxic lymphocyte differentiation are largely 
unexplored. We recently reported mutations in an evolutionary conserved region of intron 1 of 
UNC13D leading to severely reduced transcription and protein expression. Initially described in 
European FHL3 patients [297], the c.118-308C>T and the neighboring c.118-307G>A 
substitution were also highly prevalent in patient cohorts from Asia and North America [298–
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300]. In paper I we set out to investigate the underlying mechanisms for reduced UNC13D 
transcript levels in these patients, to shed new light on the transcriptional regulation of Munc13-
4 expression in cytotoxic lymphocytes and how mutations in non-coding region may cause 
disease.  
 
1.3 Epigenetic regulation of cytotoxic lymphocyte differentiation 
Cellular identity dictating phenotype and function is the result of distinct gene expression 
profiles that need to be stably maintained or altered upon development and differentiation. 
While transcriptome analysis can provide insights into differentiation-dependent changes in 
gene expression, it fails to sufficiently reveal the underlying mechanisms orchestrating such 
changes. DNA accessibility at gene loci is a major determining factor governing the quality and 
quantity of gene expression. Nuclear DNA is highly organized and tightly compacted in a 
chromatin structure of repeating units of nucleosomes comprised of histone octamers. 
Nucleosome remodeling upon differentiation results in chromatin changes affecting the ability 
of the transcriptional machinery to access DNA. These changes are mediated by covalent, 
post-transcriptional modifications of histones and the DNA itself [301–303]. Importantly, while 
the deposition and removal of these epigenetic marks is in part highly dynamic to allow for 
processes such as cellular differentiation, they also ensure a stable imprint of cellular identity 
and function that can be reliably passed on during cell division, features vital to adaptive 
immunity and immunological memory. 
Methylation of DNA occurs at cytosine residues within the context of CpG dinucleotides and 
methylation at gene promoter regions is usually associated with transcriptional silencing [304]. 
Maintenance and duplication of DNA methylation during mitosis is mediated by DNA 
methyltransferase (DNMT) 1 [305] while DNMT3a and DNTM3b function to deposit methyl 
groups de novo [306,304]. DNA demethylation requires further cytosine modification, resulting 
in failure to duplicate during cell division or base excision repair in non-dividing cells [307].  
Post-translational modifications of histones occur at N-terminal lysine residues and can 
positively or negatively affect transcription. Modifications may influence local charges thereby 
altering the affinity to DNA, may aid in recruitment of the transcriptional machinery or the 
assembly of repressive multi-protein complexes [308]. Among the most well studied and 
understood histone marks described to date are modifications of histone 3 by trimethylation of 
lysine 4 (H3K4me3) or lysine 27 (H3K27me3) as well as acetylation of lysine 9 (H3K9ac). 
H3K4me3 is generally associated with transcriptional activation [309] while H3K27me3 marks 
repressive chromatin. H3K9ac results in increased DNA accessibility and transcription by 
lowering the affinity to negatively charged DNA. These histone modifications are dynamically 
regulated by methyltransferases and demethylases as well as histone acetylases (HATs) and –
deacetylases (HDACs) [310–313]. Of note, HDACs are often components of repressive 
complexes bound to methylated DNA, thereby providing a link between different epigenetic 
marks [314]. 
Many insights into the changes and dynamics of the epigenetic landscape during cytotoxic 
lymphocyte differentiation emanate from studies comparing TN, TEFF and memory (TMEM) CD8+ 
T cell populations [315,316]. In a genome wide approach, Scharer et al. uncovered global 
changes in DNA methylation comparing TN and day-8 TEFF cells after LCMV infection in mice. 
Importantly, promoters, gene bodies and enhancers of effector molecules such as Ifn-γ and 
Gzmb were demethylated in TEFF compared to TN cells. In contrast, TEFF cells showed 
increased methylation at regulatory regions of genes typically expressed in TN cells such as 
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Ccr7 and Tcf7 [317]. Interestingly, transcription factor binding sites also underwent changes 
throughout differentiation. Putative binding sites for memory associated factors such as Bcl6 
were methylated, whereas c-Jun, Nfatc1 and Nfκb binding sites were demethylated in TEFF 
cells, possibly allowing for rapid binding and initiation of transcription upon activation [317]. 
Analysis of global methylation and histone marks in human CD8+ TN, TMEM and TEFF cells 
revealed stable demethylation and increased histone acetylation at effector molecule loci such 
as IFNG, TNF, PRF1 and GZMB as well as loci of the transcription factors EOMES, TBX21 
(encoding T-bet) and PRDM1 (encoding BLIMP-1) in differentiated cells [318,319]. 
Enrichment of H3K9ac in human CD8+ TMEM compared to TN cells has been shown to facilitate 
increased expression of EOMES and its targets perforin and granzyme B [320,321]. In mice, 
acquisition of H3K9ac at the Ifng locus underlies the rapid expression in memory CD8+ T cells 
[322]. Thus, increased chromatin accessibility at effector gene loci as a result of 
hyperacetylation imprints memory identity and allows for rapid and robust recall responses. 
A hallmark study by Araki et al. compared the genome-wide deposition of H3K4me3 and 
H3K27me3 with mRNA expression levels in resting or short-term activated human peripheral 
blood CD8+ TN, TEM and TCM populations [323]. On a global scale, gene expression at rest 
generally correlated positively with enrichment of H3K4me3 and negatively with H3K27me3 
deposition across the gene body. Repressed genes displayed low H3K4me3 but high 
H3K27me3 levels whereas active sites were characterized by enrichment of H3K4me3 but low 
levels of H3K27me3. Among the actively transcribed loci in memory cells were genes encoding 
transcription factors such as EOMES and BLIMP-1 as well as the cytotoxic effector molecules 
perforin, granzyme A and granzyme B. Poised and bivalent genes required TCR stimulation for 
expression in memory cells. While poised loci carried histone marks similar to active sites, 
bivalent loci were enriched for H3K4me3 as well as H3K27me3 and acquired more H3K4me3 
after activation, indicating a switch to open chromatin allowing for increased expression at 
those sites [323]. In line with these observations, experiments in mice later revealed co-
deposition of H3K4me3 and H3K27me27 at genes associated with proliferation, replication and 
differentiation in naïve CD8+ T cells. These bivalent loci rapidly switched to a permissive state 
by loss of H3K27me3 upon differentiation and included transcription factors such as T-bet, 
Eomes, Blimp-1 and Nfil3 [324]. In contrast, effector gene loci including Ifng, Prf1 and Gzmb 
acquired H3K4me3 modifications and associated with RNA polymerase II, while losing 
H3K27me3 marks in differentiated cells [324–326]. Interestingly, T-bet can bind the H3K27-
demethylase JMJD3 as well as the H3K4-methylase Set7/9 and recruit those to the Ifng locus 
[327]. These interactions are preserved among all members of the T-box family, highlighting 
the importance of T-bet and EOMES in chromatin remodeling during cytotoxic lymphocyte 
development and differentiation. 
Lineage specific transcriptional programs are mostly controlled by defined sets of “master” 
transcription factors that bind open chromatin structures and guide the transcriptional 
machinery. Lately, the importance of STATs as “pioneering” factors in lineage specification of 
CD4+ TH cell subsets has become apparent, linking environmental cytokine cues to epigenetic 
changes instructing differentiation. In this model, STATs serve to establish open chromatin at 
lineage specific loci, facilitating access of “master” transcription factors and recruitment of 
chromatin modifiers for stable epigenetic imprints [328,329]. Given the crucial role of STATs in 
cytotoxic lymphocyte development and differentiation, similar mechanisms are likely instructing 
chromatin changes and gene transcription in NK and CD8+ T cells.  
While ample data on epigenetic changes during CD8+ T cell differentiation is available, much 
less is known about the global epigenetic make-up of developing and mature NK cells and how 
  20 
potential alterations during terminal differentiation processes are regulated to produce the 
vastly heterogeneous human NK cell repertoire. In paper II, we compared global DNA 
methylation profiles of distinct conventional and adaptive NK cell subsets as well as CD8+ TN 
and TEMRA populations to gain insights into the epigenetic patterns that govern their phenotype 
and function. To uncover the epigenetic basis for human adaptive NK cell diversification we 
also performed DNA methylation analysis of promoter regions of signaling molecules 
differentially expressed in conventional compared to adaptive NK cells. Furthermore, to better 
understand the role of non-coding regions in the development of PIDs and the molecular 
mechanisms leading to acquisition of cytotoxic potential, we investigated the transcriptional 
and epigenetic regulation of Munc13-4 expression in paper I. 
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2 RESULTS AND DISCUSSION 
In the five papers included in my thesis, I have investigated the differentiation as well as 
phenotypic and functional diversification of human cytotoxic lymphocyte subsets in health and 
disease. In paper I, we uncovered how the potential for lytic granule exocytosis is acquired and 
transcriptionally regulated throughout cytotoxic lymphocyte differentiation. Paper II describes 
the epigenetic diversification of differentiated, CMV-associated human adaptive NK cells, while 
papers III and IV provide evidence for their longevity. Finally, in paper V we determined the 
phenotypic and functional heterogeneity of CD8+ TRM cells in human skin and how they may 
contribute to local immunopathology. 
2.1 The transcriptional regulation of cytotoxic lymphocyte degranulation 
Cytotoxic lymphocytes kill target cells by polarized release of cytolytic granules containing 
perforin and granzymes [2]. Genetic defects in lymphocyte cytotoxicity result in susceptibility to 
viral infections and are the underlying cause of familial hemophagocytic lymphohistiocytosis 
(FHL) as the inability to clear infections as well as to dampen the immune response by killing 
activated immune cells lead to hyperactivation and hyperinflammation [23]. While the 
transcriptional regulation of lytic granule constituents such as perforin and granzymes are 
increasingly well understood [330], the mechanisms governing the expression of components 
of the exocytic machinery are largely unexplored. Munc13-4 expression is obligatory for lytic 
granule exocytosis by NK and effector CD8+ T cells, and homozygous mutations in UNC13D, 
encoding Munc13-4, are associated with FHL3 [289]. We previously described non-coding 
mutations in a conserved region of UNC13D intron 1 that resulted in severely decreased 
mRNA levels in lymphocytes and were causative of substantial proportions of FHL3 cases in 
Scandinavia, Asia and North America [297–300]. Utilizing theses findings, we set out to study 
the transcriptional regulation of Munc13-4 in cytotoxic lymphocyte subsets (paper I). 
Ubiquitous UNC13D transcription was previously reported among hematopoietic cells lineages, 
without specifically addressing transcription in naïve and cytotoxic populations [289]. 
Surprisingly, we found that Munc13-4 protein was upregulated in differentiated CD8+ effector T 
cells and CD56dim NK cells relative to immature or naïve subsets as well as non-cytotoxic B 
and CD4+ T cells. In contrast, the expression of other known mediators of lytic granule 
exocytosis such as Munc18-2 and syntaxin-11 was similar in all lymphocyte populations or 
correlated less stringently with cytotoxic potential.  
Prediction of transcription factor binding sites revealed that the FHL3-causing UNC13D c.118-
308C>T mutation was located in a consensus ETS family transcription factor motif flanked by 
potential STAT sites. ETS factors are important regulators of early lineage commitment in 
hematopoietic cells and play key roles in lymphocyte development and function [331]. ETS-
family members drive expression of perforin in murine cytotoxic T cells [332] and the IL-2 
receptor β-chain CD122 in human T cell lines [333]. Moreover, the family member MEF has 
been shown to facilitate murine NK cell development and perforin expression [334]. Similarly, 
ETS-1 is critical for early NK cell development by promoting expression of the transcription 
factors T-bet and ID2 [335,336]. 
We found that the ETS family member ELF1 directly bound the evolutionary conserved region 
in intron 1 of UNC13D. The role of ELF1 in cytotoxic lymphocyte biology is largely unknown. 
ELF1-deficient mice show normal NK cell and T cell numbers but severely reduced NKT cell 
frequencies and cytokine production [337]. T and NK cell function was not addressed in this 
study. 
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A high density of binding sites for other cytotoxic lymphocyte associated transcription factors 
and a conserved transcriptional start site in the intron 1 region suggested a potential role as 
lymphocyte-specific alternative promoter. We detected the conventional and an additional, 
shorter UNC13D transcript with an alternative first exon that originated from intron 1. 
Importantly, we found increased levels of the alternative transcript in NK and CD8 T cells 
opposed to lower levels in B cells and CD4+ T cells from healthy controls. Transcription from 
the alternative start site was virtually absent in monocytes and all patient cells carrying the 
homozygous intronic mutations. While the conventional transcript was present in all subsets 
examined and slightly elevated in monocytes from healthy donors, patient samples uniformly 
showed residual but severely decreased transcription. Generating isoform specific Munc13-4 
antibodies, we have confirmed that the alternative Munc13-4 isoform is preferentially 
expressed in NK cells and T cells (Galgano, unpublished observations). Our results thus imply 
a role for the UNC13D intron 1 regulatory element as lymphocyte-specific alternative promoter 
as well as enhancer for the conventional promoter. 
Surprisingly, ELF1 protein was broadly expressed in primary lymphocyte populations including 
B cells and CD4+ T cells. Furthermore transcription from a luciferase reporter construct was 
independent of ELF1, suggesting that ELF1-binding alone was insufficient to drive increased 
Munc13-4 expression upon cytotoxic lymphocyte differentiation. We thus speculated that 
ELF1-binding facilitated recruitment of additional factors to the intronic region responsible for 
enhanced Munc13-4 expression.  
As mentioned above, our analysis of the intronic region predicted putative STAT sites directly 
up- and downstream (5’ and 3’) of the ELF1 site. Importantly, IL-12-induced STAT4 signaling 
plays a critical role in acquisition of cytotoxicity and T-bet expression in mouse CD8+ T cells 
[180,338].  STAT4 also targets the PRF1 locus in the human NK cell line NKL [339] as well as 
the Ifng and IL12RB2 loci during murine and human TH1 differentiation, respectively [340,341]. 
We found that STAT4 levels were highest in differentiated CD8+ T cells and NK cells from 
healthy donors, correlating with Munc13-4 expression and cytotoxic potential. Furthermore, 
STAT4 bound the 5’ but not the 3’ STAT site and that binding was at least partially ELF1-
dependent. STAT4 Chromatin immunoprecipitation (ChIP) confirmed binding of STAT4 and 
RNA polymerase II to the intron 1 region in primary NK cells.  
STAT4-dependent regulation of murine Ifng and human IL12RB2 loci requires recruitment of 
BRG1, a component of the SWI-SNF chromatin-remodeling complex, and deposition of active 
histone marks [340,341]. We found that BRG1 expression mirrored STAT4 and Munc13-4 
patterns and was highly induced in cytotoxic CD8+ T cell and NK cells but not naïve or non-
cytotoxic primary human lymphocyte subsets. Allele specific PCR after ChIP revealed 
enrichment of STAT4 and BRG1 at UNC13D WT but not mutated intron 1 regions in NK cells 
from a heterozygous carrier with the UNC13D c.118-308C>T mutation. Furthermore, 
enrichment of the active histone mark H3K27ac was detectable but strongly reduced at the 
mutated compared to the WT allele. We next confirmed chromatin remodeling and DNA 
accessibility at the UNC13D locus by high-resolution ChIP analysis using antibodies against 
STAT4, BRG1, H3K4me3 and H3K27ac. We found enrichment of STAT4 and BRG1 binding at 
intron 1 as well deposition of the active histone marks H3K4me3 and H3K27ac throughout the 
conventional and intron 1 promoters in primary NK cells and effector CD8+ T cells. 
Congruently, using formaldehyde-assisted isolation of regulatory elements (FAIRE) analysis 
[342], we detected enrichment of nucleosome-free regions at the conventional and alternative 
promoters in NK cells and effector CD8+ T cells compared to naïve T cells and B cells. 
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As Munc13-4, STAT4 and BRG1 were highly expressed in differentiated CD8+ effector 
compared to naïve T cells, we investigated the signals and dynamics underlying the induction 
of those proteins by mimicking differentiation in vitro. Surprisingly, only anti-CD3/CD28 
stimulation triggered expression of all proteins and STAT4 phosphorylation, albeit 
comparatively low induction of Munc13-4. BRG1 and STAT4 were induced rapidly, followed by 
increases in Munc13-4 expression. As STAT4 phosphorylation preceded upregulation of 
Munc13-4, we speculated that it could promote Munc13-4 induction upon TCR engagement. 
Indeed, transfection with STAT4 siRNA prior to TCR stimulation prevented Munc13-4 but not 
BRG1 induction in naïve CD8+ T cells. 
In summary, we found that acquisition of cytotoxic potential upon cytotoxic lymphocyte 
differentiation correlated with upregulation of Munc13-4 expression. FHL3-associated UNC13D 
c.118-308C>T mutations abrogated binding of the transcription factor ELF1 and recruitment of 
STAT4 to a conserved intronic region that functioned as an enhancer as well as promoter for 
an alternative Munc13-4 isoform in cytotoxic lymphocytes. Failure to recruit STAT4 prevented 
BRG1-mediated chromatin remodeling and deposition of active histone marks. Moreover, 
STAT4 knockdown inhibited TCR-mediated Munc13-4 induction in naïve CD8+ T cells, 
highlighting the importance of STAT4 in acquisition of lymphocyte cytotoxicity upon 
differentiation (Figure 4). 
 
 
Figure 4. Transcriptional regulation of Munc13-4 expression during cytotoxic lymphocyte 
differentiation. Binding of ELF1 in intron 1 of UNC13D facilitates recruitment of STAT4 and the 
chromatin remodeler BRG1, both of which are strongly upregulated upon cytotoxic lymphocyte 
differentiation. This allows for increased DNA accessibility and transcription of the conventional as 
well as induction of a novel isoform from an alternative intronic UNC13D promoter, required for the 
acquisition of cellular cytotoxicity. 
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Our results may thus at least partially explain the observed defects in NK cell cytotoxicity in 
Stat4-, IL12rb1 and IL12rb2-deficient mice [343–345] and suggest a central role for STAT4 
signaling in lymphocyte cytotoxicity. In line with previous studies reporting TCR-dependent 
induction of STAT4 in human CD4+ and murine CD8+ T cells [346,347], we detected a rapid 
increase in protein expression and, curiously, STAT4 phosphorylation after CD3/CD28 
stimulation in vitro. While this was sufficient to drive Munc13-4 expression in naïve cells, further 
experiments to determine degranulation capacity and cytotoxic potential following TCR 
signaling alone would have been tempting. Furthermore, given the role of STAT4 and BRG1 in 
chromatin remodeling of the IL12RB2 locus in TH1 cells [340], our results suggest a 
requirement for TCR-mediated induction of both proteins to render naïve CD8+ T cells IL-12-
responsive and allow for differentiation into potent effector and memory subsets. Therefore, 
analysis of IL12RB2 expression and IL-12-responsiveness before and after CD3/CD28 
stimulation of naïve CD8+ T cells in vitro could be interesting. 
The mechanisms of TCR-mediated STAT4 phosphorylation remain obscure, but the delayed 
responses imply an indirect rather than direct involvement of the TCR signaling pathway. A 
previous report described paracrine/autocrine activation of STATs in primary T cells following 
TCR and co-receptor engagement which could be blocked by addition of, among others, anti-
IFN-γ antibodies [348]. Although naïve CD8+ T cells lack immediate IFN-γ production, a similar 
mechanism due to “contamination” with recently described stem cell memory T (TSCM) cells 
may be responsible for our observations. TSCM display a naïve cell surface phenotype but 
express CD95 and produce IFN-γ, IL-2 and TNF upon activation [349]. 
Although mechanistic insights are missing, STAT4 single nucleotide polymorphisms (SNPs) 
are associated with human disease susceptibility. For example, a SNP resulting in reduced 
STAT4 expression increases the risk for hepatitis B virus-related hepatocellular carcinoma 
[350]. Furthermore, STAT4 SNPs are linked to complex autoimmune disorders such as 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren’s syndrome and early 
onset type 1 diabetes (T1D) [351–353]. Our findings of STAT4-mediated regulation of Munc13-
4 expression and cytotoxic lymphocyte function may thus aid in understanding the underlying 
mechanisms of such conditions and motivate targeted intervention strategies. STAT4 ChIP 
sequencing will prove useful to identify additional targets in cytotoxic lymphocytes and, in 
combination with analysis of histone modifications and DNA methylation, provide new insights 
into how STAT4 epigenetically contributes to cytotoxic lymphocyte identity. 
We also demonstrated transcription of a lymphocyte-specific alternative Munc13-4 isoform 
predicted to be 19 amino acids shorter and encode a unique N-terminal amino acid sequence. 
Future investigations will be needed to determine the precise roles of the conventional and 
alternative Munc13-4 isoforms in cytotoxic lymphocyte degranulation. As the UNC13D c.118-
308C>T mutation completely abolished transcription of the alternative isoform and no disease 
causing mutations in the first exon of the conventional isoform have been described to date, 
the alternative isoform is likely to be critical for lymphocyte cytotoxicity. To this end, we have 
started to examine the roles of the different isoforms in vesicle trafficking and degranulation 
using isoform-specific monoclonal antibodies. 
 
2.2 The epigenetic signature of adaptive NK cell diversity 
Human NK cells are phenotypically and functionally remarkably heterogeneous, but the 
underlying differentiation processes are only beginning to be understood. Cytokine-producing 
but poorly cytotoxic CD56bright NK cells mature into CD56dim NK cells that further differentiate 
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into subsets with diverse cell surface receptor expression and functional potential [354]. 
Generally, loss of CD62L and acquisition of CD57 as well as inhibitory self-KIRs are associated 
with increased cytotoxicity and cytokine responses to target cell stimulation [16,118,119]. 
Following cytomegalovirus infection, subsets of murine and human NK cells have recently 
been ascribed adaptive immune features such as long-term survival and increased effector 
functions upon re-stimulation. In humans, these so-called adaptive NK cells often express 
DAP12-coupled NKG2C or activating KIRs and are educated by inhibitory receptors for self-
MHC class I [137,140,145]. CMV-associated adaptive NK cells also lose expression of the 
ITAM-bearing intracellular signaling adaptor FcεRγ. These cells show severely impaired 
responses to cancer cell lines but, surprisingly, elevated effector function when stimulated 
through the Fc receptor CD16 [146,147]. Besides FcεRγ, NK cells express the homologous 
signaling adaptor CD3ζ, bearing three ITAMs in its cytoplasmic tail compared to only one in 
FcεRγ [55], which has been suggested to allow for greater responses downstream of CD16. 
Curiously, in addition to FcεRγ and CD3ζ, NK cells express other pairs of seemingly redundant 
intracellular signaling molecules including the SYK-family kinases SYK and ZAP-70 [355] and 
the SAP-family adaptors SAP and EAT-2 [356]. We thus hypothesized that differential 
expression of signaling molecules may provide a means to modulate signaling properties and 
tune NK cell activation thresholds and effector functions (paper II).  
To this end, we assessed protein expression of the homologous transmembrane adaptors 
FcεRγ and CD3ζ, the SYK family kinases ZAP-70 and SYK as well as the SAP-family adaptors 
SAP and EAT-2 in CD56dim peripheral blood NK cells. We found that the T cell-associated 
signaling molecules CD3ζ, ZAP-70 and SAP were uniformly expressed. In contrast, many 
donors showed downregulation of one or more of the B/myeloid cell-associated signaling 
proteins FcεRγ, SYK and EAT-2 in subsets of cells. Suggesting a critical role for CMV, loss of 
signaling protein expression correlated with CMV seropositivity but not age or sex. To 
determine the influence of acute CMV infection on the generation of NK cells lacking signaling 
protein we examined a cohort of hematopoietic cell transplant (HCT) recipients of allogeneic 
umbilical cord blood grafts. We observed development of NK cells lacking signaling protein 
expression only in recipients that reactivated CMV but not in patients that were CMV 
seronegative or did not reactive latent virus. Our data thus provided a causative link between 
acute viral infection and downregulation of signaling proteins in NK cells.  
Congruent with an adaptive NK cell phenotype, loss of signaling molecules correlated with 
NKG2C expression and decreased NKp30 staining. Interestingly, downregulation of FcεRγ 
correlated strongly with reduced NKp30 surface levels, suggesting that NKp30 couples 
exclusively to FcεRγ without contribution of CD3ζ for surface retention. In addition to NKG2C, 
the FcεRγ– compartment was enriched for activating KIRs, implicating a vital role for DAP12-
mediated signaling for expansion similar to Ly49H+ cells in mice [134]. Generally, frequencies 
of NKG2A were decreased, while those of inhibitory KIRs elevated within FcεRγ– subsets. 
Nevertheless, distinct expansions of FcεRγ– cells expressing inhibitory receptors for self-MHC 
class I in combination with DAP12-coupled NKG2C or activating KIRs could be detected. 
Importantly, we frequently identified adaptive NK cell subsets lacking expression DAP12-
coupled receptors or inhibitory self-KIRs. Thus, we uncovered a previously unappreciated 
diversity of human adaptive NK cells based on the differential expression of intracellular 
signaling molecules. Potential functional consequences of such heterogeneity will be 
discussed. 
Intrigued by the observation of tri-modal and seemingly stochastic expression patterns of 
B/myeloid-associated signaling molecules, we hypothesized that allele-specific, epigenetic 
silencing of signaling molecule loci contributed to the diversification processes that generate 
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human adaptive NK cell heterogeneity. Importantly, global DNA methylation changes enforcing 
memory and effector transcriptional programs have been shown to accompany CD8+ T cell 
differentiation [317,357]. Consistent with protein expression, we observed extensive promoter 
DNA methylation in adaptive NK cells and T cells but not canonical NK cells. Expanding on 
these findings, we perfomed genome-wide DNA methylation analysis. In line with our results on 
promoter DNA methylation, global adaptive NK cell profiles resembled those of T cells while 
being markedly different compared to late mature and, even more pronounced, early mature 
NK cells. 
Given that global changes in DNA methylation have been demonstrated to profoundly impact 
the transcriptional profile during CD8+ T cell differentiation [317], we performed gene 
expression arrays. As expected, we observed substantial upregulation of KLRC2 transcripts 
encoding NKG2C isoform as well as severely reduced FCER1G transcription, confirming the 
quality of our donor selection and sorting strategy. Comparing DNA methylation and gene 
expression, hypermethylation of probes in proximity to the transcriptional start site (TSS) 
generally correlated with a reduction in transcript levels and vice versa. It is important to note 
that due to differing sorting strategies, gene expression and DNA methylation data were 
derived form different donors using different phenotypic parameters. Intracellular stainings of 
signaling proteins to stringently define adaptive NK cell subsets still allowed for isolation of 
genomic DNA and methylation analysis, while this protocol did not support RNA-based gene 
expression analysis. Using the same donors and subsets would have likely resulted in even 
better correlation between DNA methylation and transcription. Nevertheless, changes in 
methylation and transcript levels in adaptive NK cells correlated with protein expression and 
were consistent previous observations [137,145]. 
As the transcriptional regulation of human adaptive NK cell differentiation and function were 
largely unknown, we next focused on differentially expressed transcription factors in adaptive 
compared to canonical NK cells. Among all transcription factors, transcript levels of the BTB-
zinc-finger (BTB-ZF) family member promyelocytic leukemia zinc finger (PLZF), encoded by 
ZBTB16, were the most differentially regulated and strongly reduced in adaptive NK cells. 
PLZF protein expression was uniformly downregulated in adaptive NK cells marked by loss of 
FcεRγ, SYK and/or EAT-2. BTB-ZF transcription factors can recruit co-factors for chromatin-
remodeling, orchestrate changes in DNA methylation, and regulate lymphoid development and 
function [358–360]. PLZF ChIP analysis in primary NK cells revealed enrichment at FcεRγ, 
SYK and EAT-2 but not CD3ζ, ZAP-70 or SAP promoters, suggesting an active role for PLZF 
in regulation of signaling protein expression. Besides its potential role as global chromatin 
remodeler, PLZF controls innate programs of NKT and γδT cell lineages and regulates 
expression of a limited set of genes including IL-12 and IL-18 receptor chains [361–364]. 
Indeed, IL12RB2 and IL18RAP transcript levels were downregulated in adaptive compared to 
canonical NK cells, resulting in severely reduced downstream signaling as well as a complete 
lack of IFN-γ expression after cytokine stimulation. As adaptive NK cells had previously been 
shown to display reduced responsiveness to IL-12 and IL-18 [145], we now provided a link 
between loss of the transcription factor PLZF and adaptive NK cell function. Interestingly, IL-12 
can also induce expression of the inhibitory receptor NKG2A and impede NKG2C-mediated 
lysis of HLA-E expressing target cells [365]. It is tempting to speculate that reduced IL-12-
responsiveness prevents adaptive NK cell inhibition thus allowing for killing of virus-infected 
cells. 
Zbtb32, another member of the BTB-ZF family, has been shown to facilitate the proliferative 
burst of murine Ly49H+ memory-like NK cells after MCMV challenge by antagonizing the anti-
proliferative effects of Blimp-1 (Beaulieu 2014). Although transcript levels of ZBTB32 were 
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equally low in adaptive compared to canonical NK cells, we detected extensive demethylation 
of probes close to the TSS in adaptive NK cells and effector CD8+ T cells contrasting canonical 
NK cells and, to a lesser degree, naïve T cells. This may reflect a poised state facilitating the 
rapid expression of ZBTB32 in adaptive NK cells provided the appropriate stimulus. 
Surprisingly, recent data demonstrate cooperation between Zbtb32 and Blimp-1 to prevent 
hyperproliferation of anti-viral cells and promote memory formation in CD8+ T cells after LCMV 
challenge in mice [366]. The precise roles of ZBTB32 in human adaptive NK cell expansion 
and differentiation remain to be addressed but are potentially more complex than initially 
appreciated. 
NK cells are also implicated in immunoregulatory killing of activated T cells and antigen-
presenting cells to fine-tune adaptive immune responses and maintain immune homeostasis 
[23,367–370]. Interestingly, experiments in mice suggest that NK cell suppress CD4+ and 
follicular helper T (TFH) cells thereby inhibiting generation of long-lived virus-specific memory T 
and B cells as well as production of antiviral antibodies after acute infection [371]. Furthermore, 
recent data show that upregulation of NK cell-associated genes negatively correlates with 
antibody responses and protection in a clinical trial investigating the efficacy of malaria 
vaccines [372]. We found that adaptive NK cells lacking FcεRγ or EAT-2 failed to respond to 
stimulation with activated autologous T cells. Curiously, SYK single-positive cells remained 
responsive to activated T cells, implicating a role for NCRs and SLAMFRs in recognition of 
autologous hematopoietic cells, which is in line with previous reports [87,367]. Thus, the role of 
adaptive NK cells may shift to surveillance of virus-infected cells as opposed to regulation of 
other immune cells, which may ultimately promote formation of pathogen-specific memory B 
and T cell populations. 
In summary, we found that human CMV-driven adaptive NK cells lack expression of the 
B/myeloid-associated signaling molecules FcεRγ, SYK and EAT-2 in a variegated manner. 
Such silencing correlated with promoter DNA methylation and a global DNA methylation profile 
that approximated differentiated CD8+ cytotoxic effector T cells. Furthermore, adaptive NK cell 
differentiation was accompanied by downregulation of the transcription factor PLZF, rendering 
cells unresponsiveness to innate cytokines (Figure 5). Interestingly, adaptive NK cells also 
failed to respond to autologous activated T cells, suggesting a specialized role in recognition of 
infected cells. 
The exact molecular mechanisms generating adaptive NK cell diversity during differentiation 
remain to be elucidated, but may be stochastic and asymmetric in nature, similar to what has 
been observed in CD8+ T cell differentiation from single, naïve precursors [373–376]. 
Interestingly, a recent study by Freund et al. showed that signals from activating receptors 
were critical for murine NK cell differentiation and acquisition of some Ly49 receptors by 
regulating the probabilistic switch function of their promoters [377]. Thus, strong activating 
signals could drive NK cell differentiation in general and adaptive NK cell diversification in 
particular. While NKG2C engagement by HLA-E on infected cells has been considered the 
main driver of adaptive NK cells expansion and differentiation, recent data also suggest 
contributions from other receptors as individuals with homozygous deletions in KLRC2, 
encoding NKG2C, displayed normal frequencies of adaptive NK cells [378]. Adaptive NK cells 
uniformly express the receptor CD2 and Liu et al. demonstrated that CD2 synergized with 
CD16 stimulation on adaptive but not canonical NK cells. CD2-engagement by its ligand CD58 
on CMV-infected, antibody-opsonized target cells could thus drive adaptive NK cell 
differentiation and diversification independent of NKG2C.  
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Figure 5. Human adaptive NK cell diversification. CMV infection drives the development of 
epigenetically heterogeneous adaptive NK cell subsets (red shades; the size of the subsets reflects 
the relative frequency among adaptive CD56dim NK cells) characterized by DNA methylation-
dependent silencing of the transcription factor PLZF (ZBTB16) and the signaling proteins FcεRγ, 
SYK and EAT-2 (FCER1G, SYK and SH2D1B). Downregulation of PLZF results in loss of IL-12 and 
IL-18 receptor components. Stochastic, allelic methylation of signaling protein promoters generates 
a diverse adaptive NK cell repertoire with altered target cell specificity by impinging on SLAM family 
receptor (SLAMFR), NKp30 and NKp46 signaling. DNA hypomethylation at IFNG and TNF loci 
allows for increased production of IFN-γ and TNF upon engagement of ITAM-coupled receptors on 
adaptive NK cells. Adapted from [379]. 
 
While canonical NK cell differentiation pathways appear mostly linear and progressive [101], it 
is still debated whether human adaptive NK cells continue to differentiate and progressively 
acquire adaptive NK cell features, i.e. loss of additional signaling molecules. Our data suggest 
a stable phenotype and distribution of the adaptive NK cell repertoire for at least 35 months in 
a given donor. Any attempts to induce or alter human adaptive NK cell differentiation in our or, 
to the best of our knowledge any other laboratory, have hitherto been unsuccessful. 
Furthermore, individuals often display a limited number of stable, “clonal-like” adaptive NK cell 
expansions. It is thus highly likely that a distinct adaptive NK cell phenotype and repertoire is 
maintained once generated. How such donor-dependent repertoires are shaped in the first 
place remains to be shown, but could involve the site and type of CMV-infected target cells, co-
infections with other viruses or the genetic background of a given donor. In this regard, twin 
studies could be insightful to determine the influence of nature and nurture on the development 
of distinct adaptive NK cell subsets. In addition, the underlying causes determining the size of 
the adaptive NK cell pool and why some individuals lack such cells despite CMV exposure are 
of great interest. Here, correlating the CMV-specific adaptive immune response with the 
adaptive NK cell frequency after primary infection could provide clues regarding the broad 
distribution observed in the healthy cohorts investigated to date. 
In line with previous observations describing DNA demethylation at the INFG locus in NKG2C+ 
NK cells [142], we detected extensive hypomethylation at IFNG as well as TNF loci in adaptive 
NK cells, which is likely to contribute to increased transcription and cytokine production. NK cell 
education by inhibitory receptors for self-MHC class I [15–17] as well as decreased expression 
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[380] or engagement [381] of activating receptors have been linked to increased NK cell 
function. We speculate that loss of intracellular signaling protein expression may have similar 
effects by reducing tonic signaling from activating receptors resulting in NK cell desensitization 
through epigenetic remodeling at and increased accessibility of cytokine loci. 
 
2.3 Evidence for human adaptive NK cell longevity 
Adaptive or memory-like NK cell subsets expand and persist after CMV infection in mice and 
man [134,137,140,141,143,144]. In paper II, we found that the size and phenotype of a donor-
specific adaptive NK cell repertoire at steady-state, defined by expression patterns of surface 
receptors and intracellular signaling proteins, remains remarkably stable for up to 35 months. 
Nevertheless, it is still unclear whether human adaptive NK cells are continuously replenished 
by cells differentiating from hematopoietic progenitors and immature NK cells or undergo slow, 
homeostatic turnover similar to B and T cell memory populations [382,383]. To address this 
issue, we utilized samples from patients with bone marrow disorders associated with GATA2 
haploinsufficiency (paper III) or acquired somatic PIGA mutations in hematopoietic stem and 
progenitor cells (HSPCs) underlying paroxysmal nocturnal hemoglobinuria (PNH) (paper IV).  
The transcription factor GATA-2, encoded by the GATA2 gene, is required for HSPC survival 
and proliferation [153,154]. In humans, heterozygous loss-of-function mutations are associated 
with progressive loss of monocytes, DCs, B cells and NK cells resulting in immunodeficiency 
and increased susceptibility to certain infections [155–158]. In some patients, subsets of 
differentiated NK cells accumulate, which led us to hypothesize that adaptive NK cells could 
persist in the absence of HPSCs and thus prove their longevity or potential for homeostatic 
turn-over, independent of constitutive cellular output from the bone marrow. Indeed, in a cohort 
of patients with heterozygous GATA2 mutations that retained sizeable frequencies of 
peripheral blood NK cells, we found that these cells almost uniformly displayed phenotypic and 
functional characteristics of adaptive NK cells as defined in paper II. Previously, Mace et al. 
reported GATA-2 expression in CD56bright but not CD56dim NK cells, linking GATA2 
haploinsufficiency to the specific loss of CD56bright NK cells in patients [163]. Using multicolor 
flow cytometry, we were not able to recapitulate those findings as GATA-2 expression was 
confined to CD34+ HSPCs in bone marrow and blood. Instead, we found that CD3–CD14–
CD16–CD20–CD56– lineage-negative (Lin–) cells from patients with heterozygous GATA2 
mutations displayed a severely reduced capacity to generate mature NK cells in an ex vivo NK 
cell expansion and differentiation protocol. Examination of Lin– cells revealed significantly 
diminished frequencies of NK cell progenitors in GATA2 patients compared to healthy donors, 
supporting our notion that GATA2 haploinsufficiency results in attrition of the HSPC pool and 
gradual loss of constitutively generated, short-lived canonical but not long-lived adaptive NK 
cells (Figure 6).  
In contrast to individuals with GATA2 deficiency, PNH patients with acquired X-linked PIGA 
mutations in HSPCs have not been reported to develop immunodeficiency, but generally 
present with decreased leukocyte counts compared to healthy donors [384]. Importantly, 
despite a reduction in total NK cells numbers, the distribution and functional responses of NK 
cell subsets appear unaffected [385]. Due to a defect in the GPI-synthesis pathway, patients 
lack expression of GPI-anchored proteins on the cell surface of mature progeny arising from 
mutated HSPC clones. Loss of the GPI-anchored proteins CD55 and CD59 on red blood cells 
(RBCs) results in complement-mediated membrane attack and lysis, a main characteristic of 
disease presentation in PNH [386]. After years of stable mosaicism allowing for the detection of 
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GPI+ and GPI– leukocytes subsets in the periphery, hematopoiesis may be progressively 
dominated by HSPC clones with somatic PIGA mutations. While B and T cells mostly remain 
GPI+, neutrophils and RBCs in particular completely convert to a GPI– phenotype, likely 
reflecting the comparatively short half-life and rapid renewal from HSPCs. Similarly, CD56bright 
NK cells in some patients have been reported to mostly comprise GPI– cells, while CD56dim NK 
cells often display a more even distribution of GPI+ and GPI– cells [387]. Given that peripheral 
blood NK cells have an estimated half-life of roughly two weeks [166] and would be readily 
replenished from GPI– progenitors, we speculated that long-lived adaptive NK cells largely 
remain GPI+. We thus assessed the contribution of GPI+ and GPI– cells to canonical and 
adaptive NK cell subsets in a cohort of PNH patients with varying degrees of chimerism in the 
neutrophil compartment (paper IV). Somewhat expected and in line with previous observations 
[388], frequencies of GPI– CD56bright NK cells strongly correlated with the fraction of GPI– 
neutrophils. In contrast, CD56dim NK cells contained overall fewer GPI– cells and only a minor 
fraction of B and T cells displayed a GPI– phenotype. Importantly, we found that the vast 
majority of CD56dim adaptive NK cells retained expression of GPI-anchors even in patients with 
nearly complete conversion of neutrophils and CD56bright NK cells, suggesting homeostatic 
maintenance of adaptive NK cells for more than ten years independent of HPSCs. In contrast, 
canonical CD56dim NK cells contained mostly GPI– cells, indicating constant renewal from PIGA 
mutated progenitors (Figure 7). 
 
 
 
Figure 6. Proposed model for the accumulation of adaptive NK cells in patients with heterozygous 
GATA2 mutations. Hematopoietic progenitor cells (HPCs) support NK cell development and 
potentially CMV-associated adaptive NK cell differentiation and expansion in asymptomatic carriers. 
Gradual loss of HPCs due to GATA-2 haploinsufficiency abrogates the development of short-lived 
CD56bright and canonical CD56dim NK cells. However, patients that generated adaptive NK cells prior 
to HPC attrition may retain high frequencies of potentially long-lived adaptive NK cells with the 
propensity for homeostatic self-renewal. 
 
 
Therefore, utilizing peripheral blood samples from two cohorts of patients with bone marrow 
disorders, we demonstrate that human adaptive NK cells mirror memory T and B cells and are 
likely maintained by HSPC-independent processes. The precise molecular mechanisms 
underlying adaptive NK cell survival or homeostasis are unknown, but are at least partially the 
result of increased expression of anti-apoptotic molecules such as Bcl-2, which is induced in 
FcεRγ– adaptive NK cells [147] and has been demonstrated to mediate formation and survival 
of memory B and T cells [389–391]. Bcl-2 expression responsible for CD8+ T cell memory 
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survival and homeostasis is largely driven by IL-15 [392,393], which also supports survival of 
murine NK cells by inactivating the pro-apoptotic transcription factor FoxO3a [394]. 
Surprisingly, we have detected enhanced IL-15 sensitivity and overall higher levels of 
phosphorylated STAT5 after IL-15 stimulation in adaptive compared to canonical NK cells 
(unpublished observation). Low IL-15 concentrations could thus potentially support long-term 
survival of adaptive but not canonical NK cell. Moreover, PLZF has curiously been shown to 
predispose human NKT and MAIT cells to apoptosis as a result of increased expression of 
activated caspases [395]. Loss of PLZF expression could therefore promote adaptive NK cell 
longevity while canonical NK cells undergo continuous renewal from HSPCs. Furthermore, the 
mitophagy-mediated removal of dysfunctional mitochondria during the antiviral response has 
recently been shown to promote the generation of memory NK cells in mice [396] but a similar 
mechanism has still to be demonstrated in man. Overall, future experiments addressing the 
regulation of pro- and anti-apoptotic pathways will be needed to provide further insights into the 
mechanisms governing adaptive NK cell homeostasis and survival. This could aid in the 
development of strategies for efficacious NK cell-based cancer immunotherapy. 
 
 
Figure 7. Proposed mechanism underlying the persistence of GPI+ adaptive NK cell in PNH. 
Patients may experience CMV-driven differentiation and expansion of GPI+ adaptive NK cells before 
the acquisition of PIGA mutations in hematopoietic stem and progenitor cells (HSPCs). After 
mutation of PIGA, GPI– HSPCs progressively contribute to the development of short-lived mature 
hematopoietic cells including neutrophils as well as CD56bright and canonical CD56dim NK cells. 
However, adaptive NK cells remain GPI+, supporting the notion of HSPC-independent maintenance 
due to longevity and/or homeostatic turnover.  
 
2.4 A dichotomy of CD8+ TRM cells in human skin 
While papers I-IV investigated general concepts of lymphocyte cytotoxicity as well as human 
adaptive NK cell diversity and longevity, we studied the heterogeneity of CD8+ T cell phenotype 
and function in non-lymphoid tissue in paper V. Exposure to pathogens and commensal 
bacteria drive formation of TRM populations providing local immunity at barrier sites such as 
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skin, gut, lung and the female reproductive tract [218,256,397]. TRM cells get rapidly activated 
to combat recurrent infections but may contribute to local immunopathology as evidenced by 
focal skin diseases such as psoriasis and vitiligo [256–258]. Driven by cytokines of the IL-23/IL-
17 axis, psoriasis is characterized by hyperinflammation and hyperproliferation of epidermal 
keratinocytes [257], while vitiligo lesions display hypopigmentation caused by immune-
mediated loss of melanocytes [258]. Given the differences in the underlying mechanisms and 
disease presentation, it is likely that functionally different TRM subsets contribute to psoriasis 
and vitiligo. Functional diversity of cutaneous TRM cells with regards to cytokine expression has 
been reported but phenotypic markers reflecting such diversity have not been established 
[219]. TRM can be distinguished from circulating T cell subsets by expression of CD103 and 
CD69, which mediate tissue-retention by binding epithelial E-cadherin and antagonizing S1P1 
function, respectively [228,229,233]. Interestingly, recurrent viral infections drive the 
accumulation of anti-viral TRM cells expressing CD49a, the α-subunit of the α1β1 integrin, in non-
lymphoid tissues [230,398]. CD49a binds collagen IV, which is enriched in the basement 
membrane separating dermis and epidermis [237], and thus likely aids in positioning CD49+ 
TRM at the dermal-epidermal interface. In healthy human skin, CD49a expression is variable 
[221], which led us to speculate that CD49a might indicate functionally distinct TRM subsets with 
potentially specific contributions to human skin diseases. We thus examined the anatomical 
localization, transcriptional profiles and functional properties of CD8+ TRM cells in human skin 
from healthy donors as well as lesional skin from patients with psoriasis or vitiligo (paper V). 
In healthy human skin, CD49a expression was largely restricted to epidermal CD8+ TRM cells 
co-expressing the TRM markers CD103 and CD69. Reflecting a high degree of variation of the 
TRM cell compartment, frequencies of CD49a+ cells were variable among and even within 
donors when comparing different sites. Confocal microscopy revealed that epidermal CD8+ TRM 
cells localized to the basal membrane irrespective of CD49a expression. We next assessed 
the clonal relationships between tissue-resident and circulating effector memory CD8+ T cells 
in five donors by DNA sequencing of the TCRβ complementary-determining region 3 (CDR3). 
We found that epidermal CD49a+ CD8+ TRM cells in three donors were dominated by a single 
but different Vβ chain. Furthermore, T cell subsets isolated from peripheral blood and the 
dermis as well as CD49a– epidermal T cells generally displayed greater CDR3 diversity 
compared to CD49a+ epidermal TRM cells. Importantly, the ten most abundant TCR clones in 
epidermal CD49a+ TRM were only minimally shared with all other subsets, thus indicating a 
unique, clonally enriched population of CD8+CD69+CD103+CD49a+ TRM population in healthy 
human skin. The observed variability in size and clonal distribution of this population is likely 
reflective of the local history of pathogen exposure resulting in dominant clonal expansion. 
We next performed transcriptional profiling by RNA sequencing to determine additional 
phenotypic and potential functional differences between epidermal CD103+CD49a+ and 
CD103+CD49a– CD8+ TRM cells. Principal component analysis revealed that transcriptional 
profiles of epidermal populations clustered separately from dermal as well as peripheral blood 
T cells and, in addition, showed distinct clusters of epidermal CD49a+ and CD49a– CD8+ TRM 
cells. Interestingly, genes indicating cytotoxic function as well as anti-viral responses, 
lymphocyte activation and chemotaxis were enriched among the 92 differentially expressed 
genes comparing epidermal CD49a+ and CD49a– CD8+ TRM cells. Specifically, CD49a+ cells 
showed increased transcription of lytic granule components such as PRF1, GZMB, GZMH, 
GZMK, GNLY and NKG7 as well as IFNG and CXCR3. In contrast, CD49a+ cells displayed 
significantly decreased transcription of genes associated with IL-17 production such as IL17F, 
RORC, IL23R and CCR6 in comparison to CD49a– cells. Thus, transcriptional profiles 
implicated distinct functional specializations of epidermal CD49a+ and CD49a– CD8+ TRM cells, 
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where CD49a+ cells engage in type I and cytotoxic responses, while CD49a– cells contribute to 
IL-17-mediated inflammation. 
Surprisingly, although PRF1 and GZMB transcripts were readily detectable, freshly isolated, 
resting epidermal CD103+CD49a+ CD8+ TRM lacked perforin and granzyme B protein 
expression. This was reminiscent of murine NK cells containing abundant Prf1 and Gzmb 
mRNA but require stimulation with STAT5 cytokines IL-2 or IL-15 for protein expression [399]. 
Furthermore, IL-15 was recently proposed to act as danger signal driving TRM cell effector 
function for tissue destruction [245] and facilitates cytotoxic effector differentiation in vitro when 
produced and presented by epidermal Langerhans cells [400]. Indeed, stimulation with IL-2 
and IL-15 but not other cytokines associated with skin inflammation rapidly induced perforin 
and granzyme B protein expression specifically in CD49a+ TRM cells. In line with these 
observations, CD49a+ but not CD49a– TRM cells acquired strong cytotoxic potential and killed 
target cells in a TCR-dependent manner after priming with IL-15. Of note, prolonged TCR 
stimulation alone induced perforin and granzyme B protein expression and displayed additive 
effects when combined with IL-15 priming. As TRM cells are not confined to the skin and 
populate other barrier tissues, we examined CD49a as well as perforin and granzyme B 
expression in TRM cells isolated from gut and cervix. CD49a+ CD8+ TRM cells were readily 
detectable in gut and cervix and, surprisingly, showed significant perforin and granzyme B 
expression at rest, which was further augmented by IL-15 priming. The generally elevated 
baseline expression of perforin and granzyme B in these tissues may reflect an increased 
exposure to pathogens or commensal bacteria compared to the skin. We thus found that 
CD49a expression in human TRM cells correlates with cytotoxic potential. Specifically, 
CD103+CD49a+ CD8+ TRM cells in healthy human skin are poised for cytotoxicity and can kill 
target cells after priming with IL-2 or IL-15 alone or, even more efficiently, in combination with 
antigen. Among the potential local sources of IL-2 or IL-15 are activated T cells or 
keratinocytes and epidermal Langerhans cells [400,401], respectively. 
Besides perforin-mediated target cell killing, CD8+ T cells produce pro-inflammatory cytokines 
to fight invading pathogens. At barriers sites, T cell-derived IFN-γ and IL-17 elicit anti-viral and 
anti-fungal responses, respectively. Given the elevated IFNG transcript levels in epidermal 
CD49a+ CD8+ TRM cells and the increased transcription of RORC, associated with IL-17 
production, in epidermal CD49a– CD8+ TRM cells, we speculated that CD49a+ expression might 
separate TRM subsets with distinct cytokine profiles in human skin. Indeed, following activation 
we found preferential expression of IFN-γ in epidermal CD49a+ cells, while IL-17 production 
was largely confined to epidermal CD49a– cells. IL-15 priming resulted in a significant increase 
in production of both cytokines and even promoted IFN-γ production in epidermal CD49a– 
CD8+ TRM cells. Dermal CD8+ TRM populations produced only minimal amounts of IL-17 while 
IFN-γ was more broadly expressed in sizeable fractions of dermal CD103+ and CD103– 
subsets. As IFN-γ and IL-17 are implicated in the focal skin diseases vitiligo and psoriasis, 
respectively, we next determined the expression of CD49a, perforin and granzyme B as well as 
IFN-γ and IL-17 in resting CD8+ TRM cells from skin lesions. Frequencies of epidermal and even 
dermal CD103+ CD8+ TRM expressing CD49a were significantly increased in vitiligo but not 
psoriasis compared to healthy donors. Importantly, significant fractions of dermal and 
epidermal CD49+ cells in vitiligo readily expressed perforin and granzyme B, indicating 
previous priming by cytokines and/or TCR stimulation. This notion was further supported by an 
increased frequency of total epidermal CD8+CD103+ TRM cells with the potential to produce 
IFN-γ in vitiligo compared to psoriasis lesions or healthy skin. Moreover, although epidermal 
CD49a– cells readily produced IFN-γ, frequencies of IFN-γ+ cells were significantly higher 
among CD49a+ cells. In contrast, epidermal CD8+CD103+ TRM cells in psoriasis were primed for 
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IL-17 production and frequencies of IL-17+ cells after activation were significantly elevated in 
CD49a– compared to CD49a+ cells.  
In summary, we uncovered a functional specialization of human skin CD8+ TRM cells in regards 
to cytotoxicity and cytokine production, which was preserved and enforced in the focal skin 
diseases vitiligo and psoriasis. In healthy skin, epidermal CD8+CD103+CD49a+ TRM cells were 
poised for IFN-γ production and cytotoxicity, and rapidly induced expression of perforin and 
granzyme B upon priming with IL-2 or IL-15, facilitating target cell killing. Importantly, primed 
CD8+CD103+CD49a+ TRM cells accumulated in the dermis and epidermis of vitiligo lesions 
where they likely mediate the destruction of melanocytes. In contrast, epidermal 
CD8+CD103+CD49a– TRM cells excelled at IL-17 production and were enriched in psoriasis 
lesions, probably contributing to the local inflammatory milieu driving keratinocyte 
hyperactivation and –proliferation (Figure 8). 
 
 
Figure 8. CD49a expression defines functionally distinct CD8+ TRM cells in healthy skin as well as 
vitiligo and psoriasis lesions. In healthy skin, CD49a+ cells (red) poised for cytotoxicity and IFN-γ 
production localize to the epidermis, while epidermal CD49a– cells (blue) possess the potential to 
release IL-17. In vitiligo, primed CD49a+ cells readily expressing perforin and granzyme B 
accumulate in the epidermis and dermis of lesional skin where they contribute to melanocyte 
destruction by cellular cytotoxicity and IFN-γ release. In contrast, psoriasis lesions are enriched for 
IL-17 producing CD49a– cells but also contain IFN-γ producers, creating a hyperinflammatory milieu. 
 
Barrier tissues represent entry sites for invading pathogens in general and viruses in particular. 
Common pathogenic viruses such as herpes simplex viruses (HSVs), human papilloma viruses 
(HPVs) and varicella zoster virus (VZV) target the human skin and establish latent or chronic 
infections [402,403]. Therefore, local deposition of CD8+ TRM cells with the capacity to rapidly 
induce anti-viral responses by IFN-γ production and lysis of infected cells represents an 
effective defense strategy against re-infection and, importantly, reactivation. As previously 
shown for murine epithelia [230,231,398], we found that cells with such function in healthy 
human skin localize to the epidermis and express CD49a, which probably serves to position 
cells at the basal membrane dividing dermis and epidermis where they can target infected 
keratinocytes. Epidermal CD49a+ cells will probably also aid in recruitment of circulating 
immune cells to fight infections, either directly by expressing chemokines such as MIP-1β, 
similar to circulating memory and effector CD8+ T cells, or indirectly by IFN-γ-induced 
chemokine production by local immune and non-immune cells [263,404].  
Prf
GzmB
Prf
GzmB
Prf
GzmB
Prf
GzmBPrf
GzmB
Prf
GzmB
RORγt
RORγt
RORγt
RORγt
RORγt
RORγt
Prf
GzmB
IFN-γ
IL-17
IL-17
IL-15
E
pi
de
rm
is
D
er
m
is
CD49a+
CD103+
CD49a–
CD103+ Melanocyte
PsoriasisHealthy SkinVitiligo
IFN-γ
Prf
GzmB
  35 
Interestingly, in contrast to circulating effector memory subsets, epidermal CD49a+ CD8+ TRM 
cells lacked perforin and granzyme B expression and relied on priming by IL-2 or IL-15 for 
cellular cytotoxicity. IL-15 in particular has been shown to be crucial for TRM cell development 
and homeostasis [243,405], and has recently been suggested to function as danger signal for 
tissue-resident T cells [245]. Besides epidermal Langerhans cells [400], epidermal 
keratinocytes produce IL-15, which may be boosted by IFN-γ [406]. Surprisingly, IL-15 mRNA 
can be readily detected in freshly isolated epidermal keratinocytes and Langerhans cells [407]. 
Thus, low IL-15 levels could support TRM cell homeostasis at steady-state without licensing 
CD49a+ CD8+ TRM cells for cytotoxicity. Rapid IFN-γ production by CD49a+ CD8+ TRM cells 
upon infection could ultimately increase IL-15 expression and tip the balance towards cytotoxic 
effector function and tissue destruction. Given that IL-15 also promoted IL-17 production by 
epidermal CD49a– CD8+ TRM cells, this pathway may represent an attractive target for the 
treatment of cutaneous autoimmune conditions associated with aberrant TRM cell function. 
Indeed, inhibition of JAK1 and JAK3 by the small molecule tofacitinib has recently shown 
promising results for the treatment of vitiligo in humans [408]. Furthermore, antibody-mediated 
blockade of the IL-15 receptor complex in mouse models facilitated the resolution of psoriasis 
[409] and prevented hair loss associated with alopecia areata [410]. On the other hand, 
administration of recombinant IL-15, IL-15/IL-15Rα complexes or IL-15 agonists have shown 
significant potential in the treatment of cancers by inducing proliferation, redistribution and 
enhanced effector function of cytotoxic lymphocytes [411,412]. Moreover, IL-15 has been 
shown to permit TCR-independent activation and cytotoxicity of CD8+ T cells in gut epithelium 
of patients with active celiac disease [413,414]. Cytotoxicity resulting in tissue destruction was 
mediated by the activating receptor NKG2D, which binds to stress-induced ligands such as 
MICA/B and ULBPs in humans. Importantly, NKG2D ligands are also expressed early during 
malignant transformation and can be found on human melanoma cells [415,416]. In mice, skin-
resident γδT cells have been shown to protect from development of cutaneous malignancy 
after exposure to carcinogens in an NKG2D-dependent manner [417]. Therefore, IL-15 might 
broadly license epidermal CD49a+ CD8+ TRM cells to provide a first line of defense against 
tumor development by NKG2D-mediated cytotoxicity. 
Although the precise signals driving the differentiation of distinct CD8+ TRM effector subsets 
from a common naïve precursor remain to be elucidated, the cytokine environment will be of 
central importance. Additionally, a certain degree of plasticity among TRM cells, allowing to 
transition between different types of effector functions in situ, may confer greater flexibility for 
the defense against a variety of different pathogens and threats. A better understanding of the 
signals governing differentiation and effector functions of diverse, specialized TRM subsets 
could ultimately aid in developing strategies for the treatment of autoimmune disorders or 
infections, and may potentially improve vaccination efficacy through optimization of memory 
formation [418,419]. 
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3 CONCLUDING REMARKS 
NK cells and CD8+ cytotoxic T cells constitute the major subsets of human cytotoxic 
lymphocytes and protect against viral infections and cancer development. They can kill 
aberrant cells by directed release of granules containing cytotoxic proteins and produce soluble 
factors to instruct the immune response. Importantly, cytotoxic lymphocyte dysfunction may 
result in disease. Defects in cytotoxicity cause severe susceptibility to viruses and 
hyperinflammation due to an inability to clear infected cells as well as activated immune cells. 
On the other hand, unrestrained activation may lead to destruction of healthy tissue and 
autoimmunity. In this thesis, I have examined different aspects of human cytotoxic lymphocyte 
differentiation to expand our understanding of i) the mechanisms underlying the acquisition of 
cytotoxicity, ii) the phenotypic and functional diversification in response to cytomegalovirus as 
well as iii) the contribution of distinct of skin-resident T cell subsets to tailored immune 
responses in health and disease. 
In paper I, we found that expression of Munc13-4, a factor crucial for lytic granule exocytosis, 
was upregulated during cytotoxic lymphocyte differentiation. To gain insights into the 
transcriptional regulation of UNC13D, the gene encoding Munc13-4, we utilized a previously 
identified patient mutation in a conserved region in intron 1 that abrogated mRNA transcription 
and protein expression. This mutation abolished binding of the transcription factor ELF1 as well 
as recruitment of STAT4 and the chromatin remodeler BRG1 to intron 1. This resulted in 
decreased transcription of the conventional and complete loss of an alternative transcript, 
which is most likely indispensable for lytic granule release. Similar to Munc13-4, STAT4 and 
BRG1 were upregulated during NK cell and CD8+ T cell differentiation and induced upon TCR 
stimulation of naïve CD8+ T cells in vitro. Knockdown of STAT4 prevented the induction of 
Munc13-4 expression. We thus uncovered a central role for STAT4-mediated chromatin 
remodeling and DNA accessibility in the transcriptional regulation of lymphocyte cytotoxicity. 
As STAT4 has also been shown to be critical for IFN-γ production, manipulation of STAT4 
signaling could therefore constitute a promising avenue to treat immunopathology associated 
with cytotoxic lymphocyte function. The role of the newly discovered alternative Munc13-4 
isoform in lymphocyte cytotoxicity is subject of ongoing investigations in the lab and will shed 
new light on the events governing lytic granule exocytosis.  
CMV infection leaves a pronounced imprint on the human immune system in general and the 
NK cell repertoire in particular as specific NK cell subsets expand and persist in CMV+ 
individuals. Our investigations in paper II revealed that such CMV-associated, adaptive NK 
cells lose expression of the intracellular signaling molecules FcεRγ, SYK and EAT-2, thereby 
altering signaling properties downstream of key activating NK cell receptors and target cell 
recognition. Such silencing occurred in a seemingly probabilistic manner and correlated with 
DNA hypermethylation at promoter regions. Genome-wide DNA methylation patterns of 
adaptive NK cells paralleled those of differentiated effector CD8+ T cells and were markedly 
distinct from canonical NK cells. Adaptive NK cell differentiation was furthermore accompanied 
by downregulation of the transcription factor PLZF, rendering cell unresponsive to the innate 
cytokines IL-12 and IL-18. Importantly, adaptive NK cells excelled at ADCC but failed to 
respond to activated, autologous T cells, implicating a specialized role to eliminate virus 
infected cells while potentially allowing for enhanced adaptive immune responses. Moreover, 
utilizing samples from patients with bone marrow disorders, our results in papers III and IV 
uncovered that adaptive NK cells persist long-term in the absence of HSPCs. These findings 
thus extend our knowledge concerning the mechanisms influencing NK cell specialization and 
survival. This could ultimately advance protocols for the expansion of specific, long-lived and 
highly functional NK cell subsets for the targeted immunotherapy of cancers. 
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Tissue-resident CD8+ T (TRM) cells mount rapid immune responses against invading pathogens 
at barrier sites such as the skin, gut mucosa and the female reproductive tract. While providing 
protection, they can also contribute to local immunopathology as evidenced by the focal skin 
diseases vitiligo and psoriasis. In paper V we found that healthy human skin harbors CD8+ TRM 
subsets with distinct effector functions, which can be distinguished by expression of the marker 
CD49a. Freshly isolated epidermal CD103+CD49a+ cells were poised for cytotoxicity and 
rapidly induced perforin and granzyme B expression upon IL-15 priming, facilitating target cell 
killing. Furthermore, activated epidermal CD103+CD49a+ cells produced INF-γ, while epidermal 
CD103+CD49a– cells preferentially released IL-17. This functional dichotomy of CD8+ TRM cells 
was preserved in other tissues such as gut and cervical mucosa as well as lesional skin from 
vitiligo and psoriasis patients. Importantly, vitiligo lesions contained dramatically increased 
frequencies of epidermal and dermal CD103+CD49a+ CD8+ TRM cells. These cells readily 
expressed perforin and granzyme B and were potent producers of IFN-γ, thereby most likely 
contributing to melanocyte destruction associated with vitiligo. In contrast, CD49a– TRM cells 
producing IL-17 were enriched in the epidermis of psoriasis lesions, driving local 
hyperinflammation. We thus uncovered a functional specialization of CD8+ TRM subsets in 
human skin and how those subsets may contribute to disease. Given that IL-15 stimulation 
primed cells for cytotoxicity and significantly increased production of both IFN-γ and IL-17, IL-
15 signaling may be exploited to broadly alleviate CD8+ TRM-associated autoimmune conditions 
or to mobilize cells for cancer immunotherapy. 
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